




# **SUBSTITUTE SPECIFICATION**

**(CLEAN VERSION)**

**(Serial No. 09/767,041)**

09/767,041



**PATENT**  
Attorney Docket 4726US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: \_\_\_\_\_

Date of Deposit with USPS: \_\_\_\_\_

Person making Deposit: \_\_\_\_\_

PATENT APPLICATION

**STREPTOCOCCUS SUIS VACCINES AND DIAGNOSTIC TESTS**

Inventor:

Hilda E. Smith

Attorneys:  
Allen C. Turner  
Registration No. 33,041  
Krista Weber Powell  
Registration No. 48,867  
TRASKBRITT, PC  
P.O. Box 2550  
Salt Lake City, Utah 84110  
Telephone: (801) 532-1922

## **STREPTOCOCCUS SUIS VACCINES AND DIAGNOSTIC TESTS**

[0001] **Cross-reference to Related Applications.** This application claims priority to, and is a continuation of, International Application No. PCT/NL99/00460, filed on July 19, 1999, designating the United States of America, the contents of which are incorporated herein by this reference, the PCT International Patent Application itself claiming priority from European Patent Office Application Serial No. 98202465.5 filed July 22, 1998 and European Patent Office Application Serial No. 98202467.1 filed July 22, 1998.

[0002] **Technical Field.** The invention relates to *Streptococcus* infections in pigs, vaccines directed against those infections, tests for diagnosing *Streptococcus* infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against *Streptococcus* infections.

### **Background of the Invention**

[0003] *Streptococcus species*, of which a large variety cause infections in domestic animals and man, are often grouped according to Lancefield's groups. Typing according to Lancefield occurs on the basis of serological determinants or antigens that are, among others, present in the capsule of the bacterium, and allows for only an approximate determination. Often, bacteria from different groups show cross-reactivity with each other, while other Streptococci cannot be assigned a group-determinant at all. Within groups, further differentiation is often possible on the basis of serotyping. These serotypes further contribute to the large antigenic variability of Streptococci, a fact that creates an array of difficulties within diagnosis of and vaccination against Streptococcal infections.

[0004] Lancefield group A *Streptococcus species* (Group A streptococci "GAS", *Streptococcus pyogenes*) are common in children, causing nasopharyngeal infections and complications thereof. Among animals, cattle are especially susceptible to GAS, and the resulting mastitis.

[0005] Group A streptococci are the etiologic agents of streptococcal pharyngitis and impetigo, two of the most common bacterial infections in children, as well as a variety of less common, but potentially life-threatening, infections including soft tissue infections, bacteremia, and pneumonia. In addition, GAS are uniquely associated with the post-infectious autoimmune syndromes of acute rheumatic fever and post streptococcal glomerulonephritis.

[0006] Several recent reports suggest that the incidence of both serious infections due to GAS and acute rheumatic fever has increased during the past decade, focusing renewed interest on defining the attributes or virulence factors of the organism that may play a role in the pathogenesis of these diseases.

[0007] GAS produce several surface components and extracellular products that may be important in virulence. The major surface protein, M protein, has been studied in the most detail and has been convincingly shown to play a role in both virulence and immunity. Isolates rich in M protein are able to grow in human blood, a property thought to reflect the capacity of M protein to interfere with phagocytosis, and these isolates tend to be virulent in experimental animals.

[0008] Lancefield group B *Streptococcus* ("GBS") are most often seen in cattle, causing mastitis; however, human infants are susceptible as well, often with fatal consequences. Group B streptococci (GBS) constitute a major cause of bacterial sepsis and meningitis among human neonates born in the United States and Western Europe and are emerging as significant neonatal pathogens in developing countries as well.

[0009] It is estimated that GBS strains are responsible for 10,000 to 15,000 cases of invasive infection in neonates in the United States alone. Despite advances in early diagnosis and treatment, neonatal sepsis due to GBS continues to carry a mortality rate of 15 to 20%. In addition, survivors of GBS meningitis have 30 to 50% incidence of long-term neurologic sequelae. Over the past two decades, increasing recognition of GBS as an important pathogen for human infants has generated renewed interest in defining the bacterial and host factors important in virulence of GBS and in the immune response to GBS infection.

[0010] Particular attention has focused on the capsular polysaccharide as the predominant surface antigen of the organisms. In a modification of the system originally developed by Rebecca Lancefield, GBS strains are serotyped on the basis of antigenic differences

in their capsular polysaccharides and the presence or absence of serologically defined C proteins. While GBS isolated from nonhuman sources often lack a serologically detectable capsule, a large majority of strains associated with neonatal infection belong to one of four major capsular serotypes, Ia, Ib, II or III. The capsular polysaccharide forms the outermost layer around the exterior of the bacterial cell, superficial to the cell wall. The capsule is distinct from the cell wall-associated group B carbohydrate. It has been suggested that the presence of sialic acid, in the capsule of bacteria that causes meningitis, is important for allowing these bacteria to breach the blood-brain barrier. Indeed, in *S. agalactiae*, sialic acid has been shown to be critical for the virulence function of the type III capsule. The capsule of *S. suis* serotype is composed of glucose, galactose, N-acetylglucosamine, rhamnose and sialic acid.

[0011] The group B polysaccharide, in contrast to the type-specific capsule, is present on all GBS strains and is the basis for serogrouping the organisms into Lancefield's group B. Early studies by Lancefield and co-workers showed that antibodies raised in rabbits against whole GBS organisms protected mice against challenge with strains of homologous capsular type, demonstrating the central role of the capsular polysaccharide as a protective antigen. Studies in the 1970s by Baker and Kasper demonstrated that cord blood of human infants with type III GBS sepsis uniformly had low or undetectable levels of antibodies directed against the type III capsule, suggesting that a deficiency of anticapsular antibody was a key factor in susceptibility of human neonates to GBS disease.

[0012] Lancefield group C infections, such as those with *S. equi*, *S. zooepidemicus*, *S. dysgalactiae*, and others, are mainly seen in horses, cattle and pigs, but can also cross the species barrier to humans. Lancefield group D (*S. bovis*) infections are found in all mammals and some birds, sometimes resulting in endocarditis or septicemia.

[0013] Lancefield groups E, G, L, P, U and V (*S. porcinus*, *S. canis*, *S. dysgalactiae*) are found in various hosts, causing neonatal infections, nasopharyngeal infections or mastitis.

[0014] Within Lancefield groups R, S, and T (and with ungrouped types), *Streptococcus suis* is an important cause of meningitis, septicemia, arthritis and sudden death in young pigs (4, 46). Incidentally, it can also cause meningitis in man (1). *S. suis* strains are usually identified and classified by their morphological, biochemical and serological characteristics (58, 59,

46). Serological classification is based on the presence of specific antigenic polysaccharides. So far, 35 different serotypes have been described (9, 56, 14). In several European countries, *S. suis* serotype 2 is the most prevalent type isolated from diseased pigs, followed by serotypes 9 and 1. Serological typing of *S. suis* is performed using different types of agglutination tests. In these tests, isolated and biochemically characterized *S. suis* cells are agglutinated with a panel of 35 specific sera. These methods are very laborious and time-consuming.

[0015] Little is known about the pathogenesis of the disease caused by *S. suis*, let alone about its various serotypes such as type 2. Various bacterial components, such as extracellular and cell-membrane associated proteins, fimbriae, hemagglutinins, and hemolysin have been suggested as virulence factors (9, 10, 11, 15, 16, 47, 49). However, the precise role of these protein components in the pathogenesis of the disease remains unclear (37). It is well known that the polysaccharide capsule of various Streptococci and other Gram-positive bacteria plays an important role in pathogenesis (3, 6, 35, 51, 52). The capsule enables these microorganisms to resist phagocytosis and is therefore regarded as an important virulence factor. Recently, a role of the capsule of *S. suis* in the pathogenesis was suggested as well (5). However, the structure, organization and function of the genes responsible for capsule polysaccharide synthesis ("*cps*") in *S. suis* is unknown. Within *S. suis*, serotype 1 and 2, strains can differ in virulence for pigs (41, 45, 49). Some type 1 and 2 strains are virulent, other strains are not. Because both virulent and nonvirulent strains of serotype 1 and 2 strains are fully encapsulated, it may even be that the capsule is not a relevant factor required for virulence.

[0016] Attempts to control *S. suis* infections or disease are still hampered by the lack of knowledge about the epidemiology of the disease and the lack of effective vaccines and sensitive diagnostics. It is well known and generally accepted that the polysaccharide capsule of various Streptococci and other gram-positive bacteria plays an important role in pathogenesis. The capsule enables these microorganisms to resist phagocytosis and is therefore regarded as an important virulence factor.

[0017] Compared to encapsulated *S. suis* strains, non-encapsulated *S. suis* strains are phagocytosed by murine polymorphonuclear leucocytes to a greater degree. Moreover, an increase in thickness of capsule was noted for *in vivo* grown virulent strains while no increase was

observed for avirulent strains. Therefore, these data again demonstrate the role of the capsule in the pathogenesis for *S. suis* as well.

[0018] Ungrouped *Streptococcus species*, such as *S. mutans*, causing caries in humans, *S. uberis*, causing mastitis in cattle, and *S. pneumoniae*, causing major infections in humans, and *Enterococcus faecalis* and *E. faecium*, further contribute to the large group of Streptococci.

[0019] *Streptococcus pneumoniae* (the pneumococcus) is a human pathogen causing invasive diseases, such as pneumonia, bacteremia, and meningitis. Despite the availability of antibiotics, pneumococcal infections remain common and can still be fatal, especially in high-risk groups, such as young children and elderly people. Particularly in developing countries, many children under the age of five years die each year from pneumococcal pneumonia. *S. pneumoniae* is also the leading cause of otitis media and sinusitis. These infections are less serious, but nevertheless incur substantial medical costs, especially when leading to complications, such as permanent deafness. The normal ecological niche of the pneumococcus is the nasopharynx of man. The entire human population is colonized by the pneumococcus at one time or another, and at a given time, up to 60% of individuals may be carriers. Nasopharyngeal carriage of pneumococci by man is often accompanied by the development of protection against infection by the same serotype. Most infections do not occur after prolonged carriage but follow exposure to recently acquired strains. Many bacteria contain surface polysaccharides that act as a protective layer against the environment. Surface polysaccharides of pathogenic bacteria usually make the bacteria resistant to the defense mechanisms of the host, for example, the lytic action of serum or phagocytosis. In this respect, the serotype-specific capsular polysaccharide ("CP") of *Streptococcus pneumoniae*, is an important virulence factor. Unencapsulated strains are avirulent, and antibodies directed against the CP are protective. Protection is serotype specific; each serotype has its own, specific CP structure. Ninety different capsular serotypes have been identified. Currently, CPs of 23 serotypes are included in a vaccine.

[0020] Vaccines directed against *Streptococcus* infections typically aim to utilize an immune response directed against the polysaccharide capsule of the various *Streptococcus species*, especially since the capsule is considered a primary virulence factor for these bacteria. During

infection, the capsule provides resistance against phagocytosis and thus protects the bacteria from the immune system of the host, and from elimination by macrophages and neutrophils.

[0021] The capsule particularly confers the bacterium resistance to complement-mediated opsonophagocytosis. In addition, some bacteria express capsular polysaccharides (CPs) that mimic host molecules, thereby avoiding the immune system of the host. Also, even when the bacteria have been phagocytosed, intracellular killing is hampered by the presence of a capsule.

[0022] It is generally thought that the bacterium will be recognized by the immune system through the anticapsular-antibodies or serum-factors bound to its capsule, and will, through opsonization, be phagocytosed and killed only when the host has antibodies or other serum factors directed against capsule antigens.

[0023] However, these antibodies are serotype-specific, and will often only confer protection against only one of the many serotypes known within a group of *Streptococci*.

[0024] For example, current commercially available *S. suis* vaccines, which are generally based on whole-cell-bacterial preparations, or on capsule-enriched fractions of *S. suis*, confer only limited protection against heterologous strains. Also, the current pneumococcal vaccine, which was licensed in the United states in 1983, consists of purified CPs of 23 pneumococcal serotypes whereas at least 90 CP types exist.

[0025] The composition of this pneumococcal vaccine was based on the frequency of the occurrence of disease isolates in the US and cross-reactivity between various serotypes. Although this vaccine protects healthy adults against infections caused by serotypes included in the vaccine, it fails to raise a protective immune response in infants younger than 18 months and it is less effective in elderly people. In addition, the vaccine confers only limited protection in patients with immunodeficiencies and hematology malignancies.

[0026] Thus, improved vaccines are needed against *Streptococcus* infections. Much attention is directed toward producing CP vaccines by producing the relevant polysaccharides via chemical or recombinant means. However, chemical synthesis of polysaccharides is costly, and capsular polysaccharide synthesis by recombinant means necessitates knowledge about the relevant genes, which is not always available, and needs to be determined for every relevant serotype.



## Disclosure of the Invention

[0027] The invention provides an isolated or recombinant nucleic acid encoding a capsular (*cps*) gene cluster of *Streptococcus suis*. Biosynthesis of capsule polysaccharides has generally been studied in a number of Gram-positive and Gram-negative bacteria (32). In Gram-negative bacteria, but also in a number of Gram-positive bacteria, genes which are involved in the biosynthesis of polysaccharides are clustered at a single locus.

[0028] *Streptococcus suis* capsular genes, as provided by the invention, show a common genetic organization involving three distinct regions. The central region is serotype specific and encodes enzymes responsible for the synthesis and polymerization of the polysaccharides. The central region is flanked by two regions conserved in *Streptococcus suis* which encode proteins for common functions, such as transport of the polysaccharide across the cellular membrane. However, between species, only low homologies exist, hampering easy comparison and detection of seemingly similar genes. Knowing the nucleic acid encoding the flanking regions allows type-specific determination of nucleic acid of the central region of *Streptococcus suis* serotypes, as, for example, described herein.

[0029] The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* or a gene or gene fragment derived thereof. Such a nucleic acid is, for example, provided by hybridizing chromosomal DNA derived from any one of the *Streptococcus suis* serotypes to a nucleic acid encoding a gene derived from a *Streptococcus suis* serotype 1, 2 or 9 capsular gene cluster, as provided by the invention (*see* for example, Tables 4 and 5) and cloning of (type-specific) genes as, for example, described herein. At least 14 open reading frames are identified. Most of the genes belong to a single transcriptional unit, identifying a coordinate control of these genes. The genes and the enzymes and proteins they encode, act in concert to provide the capsule with the relevant polysaccharides.

[0030] The invention provides *cps* genes and proteins encoded thereof involved in regulation (CpsA), chain length determination (CpsB, C), export (CpsC) and biosynthesis (CpsE, F, G, H, J, K). Although, at first glance, the overall organization seemed to be similar to that of the *cps* and *eps* gene clusters of a number of Gram-positive bacteria (19, 32, 42), overall

homologies are low (see, table 3). The region involved in biosynthesis is located at the center of the gene cluster and is flanked by two regions containing genes with more common functions.

[0031] The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* serotype 2, or a gene or gene fragment derived thereof, preferably as identified in FIG. 3. Genes in this gene cluster are involved in polysaccharide biosynthesis of capsular components and antigens. For a further description of such genes see, for example, Table 2. For example, a *cpsA* gene is provided functionally encoding regulation of capsular polysaccharide synthesis, whereas *cpsB* and *cpsC* are functionally involved in chain-in-chain length determination. Other genes, such as *cpsD*, *E*, *F*, *G*, *H*, *I*, *J*, *K* and related genes, are involved in polysaccharide synthesis, functioning, for example, as glucosyl or glycosyltransferase. The *cpsF*, *G*, *H*, *I*, *J* genes encode more type-specific proteins than the flanking genes which are found more-or-less conserved throughout the species and can serve as a base for selection of primers or probes in PCR-amplification or cross-hybridization experiments for subsequent cloning.

[0032] The invention further provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* serotype 1 or a gene or gene fragment derived thereof, preferably as identified in FIG. 4.

[0033] In addition, the invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* serotype 9 or a gene or gene fragment derived thereof, preferably as identified in FIG. 5.

[0034] Furthermore, the invention provides, for example, a fragment of the *cps* locus or parts thereof, involved in the capsular polysaccharide biosynthesis, of *S. suis*, exemplified herein for serotypes 1, 2 or 9, and allows easy identification or detection of related fragments derived of other serotypes of *S. suis*.

[0035] The invention provides a nucleic acid probe or primer derived from a nucleic acid according to the invention allowing species or serotype specific detection of *Streptococcus suis*. Such a probe or primer (used interchangeably herein) is, for example, a DNA, RNA or PNA (peptide nucleic acid) probe hybridizing with capsular nucleic acid as provided by the invention. Species-specific detection is provided preferably by selecting a probe or primer sequence from a species-specific region (e.g. flanking region) whereas serotype-specific detection is provided

preferably by selecting a probe or primer sequence from a type-specific region (e.g. central region) of a capsular gene cluster as provided by the invention. Such a probe or primer can be used in a further unmodified form, for example, in cross-hybridization or polymerase-chain reaction (PCR) experiments as, for example, described in the experimental part herein. The invention provides the isolation and molecular characterization of additional type-specific *cps* genes of *S. suis* types 1 and 9. In addition, we describe the genetic diversity of the *cps* loci of serotypes 1, 2 and 9 among the 35 *S. suis* serotypes known. Type-specific probes are identified. Also, a type-specific PCR, for example, for serotype 9, is provided, being a rapid, reliable and sensitive assay used directly on nasal or tonsillar swabs or other samples of infected or carrier animals.

[0036] The invention also provides a probe or primer according to the invention with at least one reporter molecule. Examples of reporter molecules are manifold and known in the art; for example, a reporter molecule can include additional nucleic acid provided with a specific sequence (e.g. oligo-dT) hybridizing to a corresponding sequence in which hybridization can easily be detected, for example, because it has been immobilized to a solid support.

[0037] Yet other reporter molecules include chromophores, e.g. fluorochromes for visual detection, for example, by light microscopy or fluorescent *in situ* hybridization ("FISH") techniques, or include an enzyme such as horseradish peroxidase for enzymatic detection, for example in enzyme-linked assays ("EIA"). Yet other reporter molecules include radioactive compounds for detection in radiation-based assays.

[0038] In a preferred embodiment of the invention, at least one probe or primer according to the invention is provided (labeled) with a reporter molecule and a quencher molecule, together with an unlabeled probe or primer in a PCR-based test allowing rapid detection of specific hybridization.

[0039] The invention further provides a diagnostic test or test kit including a probe or primer as provided by the invention. Such a test or test kit is, for example, a cross-hybridization test or PCR-based test advantageously used in rapid detection and/or serotyping of *Streptococcus suis*.

[0040] The invention further provides a protein or fragment thereof encoded by a nucleic acid according to the invention. Examples of such a protein or fragment are proteins

described in Table 2. For example, a *cpsA* protein is provided that functionally encodes regulation of capsular polysaccharide synthesis, whereas *cpsB* and *cpsC* are functionally involved in chain-in-chain length determination. Other proteins or functional fragments thereof, as provided by the invention, such as *cpsD*, *E*, *F*, *G*, *H*, *I*, *J*, *K* and related proteins, are involved in polysaccharide biosynthesis, functioning, for example, as glucosyl or glycosyltransferase in polysaccharide biosynthesis of *Streptococcus suis* capsular antigen.

[0041] The invention also provides a method of producing a *Streptococcus suis* capsular antigen including using a protein or functional fragment thereof as provided by the invention, and provides therewith a *Streptococcus suis* capsular antigen obtainable by such a method.

[0042] A comparison of the predicted amino acid sequences of the *cps2* genes with sequences found in the databases allowed the assignment of functions to the open reading frames. The central region contains the type-specific glycosyltransferases and the putative polysaccharide polymerase. This region is flanked by two regions encoding for proteins with common functions, such as regulation and transport of polysaccharide across the membrane. Biosynthesis of *Streptococcus* capsular polysaccharide antigen using a protein or functional fragment thereof is advantageously used in chemo-enzymatic synthesis and the development of vaccines which offer protection against serotype-specific Streptococcal disease, and is also advantageously used in the synthesis and development of multivalent vaccines against Streptococcal infections. Such vaccines elicit ariticapsular antibodies which confer protection.

[0043] Furthermore, the invention provides an acapsular *Streptococcus* mutant for use in a vaccine, a vaccine strain derived thereof and a vaccine derived thereof. Surprisingly, and against the grain of common doctrine, the invention provides use of a *Streptococcus* mutant deficient in capsular expression in a vaccine.

[0044] Acapsular *Streptococcus* mutants have long been known in the art and can be found in nature. Griffith (*J. Hyg.* 27:113-159, 1928) demonstrated that pneumococci could be transformed from one type to another. If he injected live rough (acapsular or unencapsulated) type 2 pneumococci into mice, the mice would survive. If, however, he injected the same dose of live rough type 2 mixed with heat-killed smooth (encapsulated) type 1 into a mouse, the mouse would die, and, from the blood, he could isolate live smooth type 1 pneumococci. At that time,

the significance of this transforming principle was not understood. However, understanding came when it was shown that DNA constituted the genetic material responsible for phenotypic changes during transformation.

[0045] *Streptococcus* mutants deficient in capsular expression are found in several forms. Some are fully deficient and have no capsule at all, others form a deficient capsule, characterized by a mutation in a capsular gene cluster. Deficiency can, for instance, include capsular formation wherein the organization of the capsular material has been rearranged, as, for example, demonstrable by electron microscopy. Yet others have a nearly fully developed capsule which is only deficient in a particular sugar component.

[0046] Now, after much advance of biotechnology and despite the fact that little is still known about the exact localization and sequence of genes involved in capsular synthesis in Streptococci, it is possible to create mutants of Streptococci, for example, by homologous recombination or transposon mutagenesis, which has, for example, been done for GAS (Wessels et al., *PNAS* 88:8317-8321, 1991), for GBS (Wessels et al., *PNAS* 86: 8983-8987, 1989), for *S. suis* (Smith, ID-DLO Annual report 1996, page 18-19; Charland et al., *Microbiol.* 144:325-332, 1998) and *S. pneumoniae* (Kolkman et al., *J. Bact.* 178:3736-3741, 1996). Such recombinant derived mutants, or isogenic mutants, can easily be compared with the wild-type strains from which they have been derived.

[0047] In a preferred embodiment, the invention provides use of a recombinant-derived *Streptococcus* mutant deficient in capsular expression in a vaccine. Recombinant techniques useful in producing such mutants are, for example, homologous recombination, transposon mutagenesis, and others, wherein deletions, insertions or (point) mutations are introduced in the genome. Advantages of using recombinant techniques include the stability of the obtained mutants (especially with homologous recombination and double crossover techniques), and the knowledge about the exact site of the deletion, mutation or insertion.

[0048] In another embodiment, the invention provides a stable mutant deficient in capsular expression obtained, for example, through homologous recombination or crossover integration events. Examples of such a mutant can be found herein, for example, mutants IOcpsB or 10cpsEF are stable mutants as provided by the invention.

[0049] The invention also provides a *Streptococcus* vaccine strain and vaccine that has been derived from a *Streptococcus* mutant deficient in capsular expression. In general, the strain or vaccine is applicable within the whole range of Streptococcal infections, including animals or man or with zoonotic infections. It is, of course, now possible to first select a common vaccine strain and derive a *Streptococcus* mutant deficient in capsular expression thereof for the selection of a vaccine strain and use in a vaccine according to the invention.

[0050] In a preferred embodiment, the invention provides use of a *Streptococcus* mutant deficient in capsular expression in a vaccine wherein the *Streptococcus* mutant is selected from the group composed of *Streptococcus* group A, *Streptococcus* group B, *Streptococcus suis* and *Streptococcus pneumoniae*. Herewith the invention provides vaccine strains and vaccines for use with these notoriously heterologous Streptococci, of which a multitude of serotypes exist. With a vaccine, as provided by the invention, that is derived from a specific *Streptococcus* mutant that is deficient in capsular expression, the difficulties relating to lack of heterologous protection can be circumvented since these mutants do not rely on capsular antigens, per se, to induce protection.

[0051] In a preferred embodiment, the vaccine strain is selected for its ability to survive, or even replicate, in an immune-competent host or host cells and thus can persist for a certain period, varying from 1-2 days to more than one or two weeks, in a host, despite its deficient character.

[0052] Although an immunodeficient host will support replication of a wide range of bacteria that are deficient in one or more virulence factors, in general, it is considered a characteristic of pathogenicity of Streptococci that they can survive for certain periods or replicate in a normal host or host cells such as macrophages. For example, Williams and Blakemore (*Neuropath. Appl. Neurobiol.*: 16, 345-356, 1990; *Neuropath. Appl. Neurobiol.*: 16, 377-392, 1990; *J. Infect. Dis.*: 162, 474-481, 1990) show that both polymorphonuclear cells and macrophage cells are capable of phagocytosing pathogenic *S. suis* in pigs lacking anti-*S. suis* antibodies; only pathogenic bacteria could survive and multiply inside macrophages and the pig.

[0053] In a preferred embodiment, the invention, however, provides a deficient or avirulent mutant or vaccine strain which is capable of surviving at least 4-5 days, preferably at least

8-10 days in the host, thereby allowing the development of a solid immune response to subsequent *Streptococcus* infection.

[0054] Due to its persistent but avirulent character, a *Streptococcus* mutant or vaccine strain, as provided by the invention, is well suited to generate specific and/or long-lasting immune responses against Streptococcal antigens. Moreover, possible specific immune responses of the host directed against a capsule are relatively irrelevant because a vaccine strain, as provided by the invention, is typically not recognized by such antibodies.

[0055] In addition, the invention provides a *Streptococcus* vaccine strain according to the invention, which strain includes a mutant capable of expressing a *Streptococcus* virulence factor or antigenic determinant.

[0056] In a preferred embodiment, the invention provides a *Streptococcus* vaccine strain, according to the invention, which includes a mutant capable of expressing a *Streptococcus* virulence factor wherein the virulence factor or antigenic determinant is selected from a group of cellular components, such as muramidase-released protein ("MRP"), extracellular factor ("EF") and cell-membrane associated proteins 60kDA heat shock protein, pneumococcal surface protein A (Psp A), pneumolysin, C protein, protein M, fimbriae, hemagglutinins and hemolysin or components functionally related thereto.

[0057] In a preferred embodiment, the invention provides a *Streptococcus* vaccine strain including a mutant capable of over-expressing the virulence factor. In this way, the invention provides a vaccine strain for incorporation in a vaccine which specifically causes a host immune response directed against antigenically important determinants of virulence (listed above), thereby providing specific protection against the determinants. Over-expression can, for example, be achieved by cloning the gene involved behind a strong promoter, which is, for example, constitutionally expressed in a multicopy system, either in a plasmid or via integration in a genome.

[0058] In yet another embodiment, the invention provides a *Streptococcus* vaccine strain, according to the invention, including a mutant capable of expressing a non-*Streptococcus* protein. Such a vector-*Streptococcus* vaccine strain allows, when used in a vaccine, protection against pathogens other than *Streptococcus*.

[0059] Due to its persistent but avirulent character, a *Streptococcus* vaccine strain or mutant as provided by the invention is well suited to generate specific and long-lasting immune responses, not only against Streptococcal antigens, but also against other antigens expressed by the strain. Specifically, antigens derived from another pathogen are now expressed without the detrimental effects of the antigen or pathogen which would otherwise have harmed the host.

[0060] An example of such a vector is a *Streptococcus* vaccine strain or mutant wherein the antigen is derived from a pathogen, such as *Actinobacillus pleuropneumonia*, *Mycoplasma*, *Bordetella*, *Pasteurella*, *E. coli*, *Salmonella*, *Campylobacter*, *Serpulina* and others.

[0061] The invention also provides a vaccine including a *Streptococcus* vaccine strain or mutant according to the invention and a pharmaceutically acceptable carrier or adjuvant. Carriers or adjuvants are well known in the art; examples are phosphate buffered saline, physiological salt solutions, (double-) oil-in-water emulsions, aluminumhydroxide, Specol, block- or co-polymers, and others.

[0062] A vaccine according to the invention can include a vaccine strain either in a killed or live form. For example, a killed vaccine including a strain having (over) expressed a Streptococcal or heterologous antigen or virulence factor is very well suited for eliciting an immune response. In a preferred embodiment, the invention provides a vaccine wherein the strain is live, due to its persistent but avirulent character; a *Streptococcus* vaccine strain, as provided by the invention, is well suited to generate specific and long-lasting immune responses.

[0063] The invention also provides a method for controlling or eradicating a Streptococcal disease in a population comprising vaccinating subjects in the population with a vaccine according to the invention.

[0064] In a preferred embodiment, a method for controlling or eradicating a Streptococcal disease is provided including testing a sample, such as a blood sample, or nasal or throat swab, feces, urine, or other samples such as can be sampled at or after slaughter, collected from at least one subject, such as an infant or a pig, in a population partly or wholly vaccinated with a vaccine according to the invention for the presence of encapsulated Streptococcal strains or mutants. Since a vaccine strain or mutant according to the invention is not pathogenic, and can be distinguished from wild-type strains by capsular expression, the detection of (fully) encapsulated



Streptococcal strains indicates that wild-type infections are still present. Such wild-type infected subjects can then be isolated from the remainder of the population until the infection has passed. With domestic animals, such as pigs, it is even possible to remove the infected subject from the population as a whole by culling. Detection of wild-type strains can be achieved via traditional culturing techniques, or by rapid detection techniques such as PCR detection.

[0065] In yet another embodiment, the invention provides a method for controlling or eradicating a Streptococcal disease including testing a sample collected from at least one subject in a population partly or wholly vaccinated with a vaccine according to the invention for the presence of capsule-specific antibodies directed against Streptococcal strains. Capsule specific antibodies can be detected with classical techniques known in the art, such as used for Lancefield's group typing or serotyping.

[0066] A preferred embodiment for controlling or eradicating a Streptococcal disease in a population includes vaccinating subjects in the population with a vaccine according to the invention and testing a sample collected from at least one subject in the population for the presence of encapsulated Streptococcal strains and/or for the presence of capsule-specific antibodies directed against Streptococcal strains.

[0067] For example, a method is provided wherein the Streptococcal disease is caused by *Streptococcus suis*.

[0068] The invention also provides a diagnostic assay for testing a sample for use in a method according to the invention including at least one means for the detection of encapsulated Streptococcal strains and/or for the detection of capsule-specific antibodies directed against Streptococcal strains.

[0069] The invention further provides a vaccine including an antigen according to the invention and a suitable carrier or adjuvant. The immunogenicity of a capsular antigen provided by the invention is, for example, increased by linking to a carrier (such as a carrier protein), allowing the recruitment of T-cell help in developing an immune response.

[0070] The invention further provides a recombinant microorganism provided with at least a part of a capsular gene cluster derived from *Streptococcus suis*. The invention provides, for example, a lactic acid bacterium provided with at least a part of a capsular gene cluster derived

from *Streptococcus suis*. Various food-grade lactic acid bacteria (*Lactococcus lactis*, *Lactobacillus casei*, *Lactobacillus plantarium* and *Streptococcus gordonii*) have been used as delivery systems for mucosal immunization. It has now been shown that oral (or mucosal) administration of recombinant *L. lactis*, *Lactobacillus*, and *Streptococcus gordonii* can elicit local IgA and/or IgG antibody responses to an expressed antigen. The use of oral routes for immunization against infective diseases is desirable because oral vaccines are easier to administer and have higher compliance rates, and because mucosal surfaces are the portals of entry for many pathogenic microbial agents. It is within the skill of the artisan to provide such micro-organisms with (additional) genes.

[0071] The invention further provides a recombinant *Streptococcus suis* mutant provided with a modified capsular gene cluster. It is within the skill of the artisan to swap genes within a Species. In a preferred embodiment, an avirulent *Streptococcus suis* mutant is selected to be provided with at least a part of a modified capsular gene cluster according to the invention.

[0072] The invention further provides a vaccine including a microorganism or a mutant provided by the invention. An advantage of such a vaccine over currently used vaccines is that they include accurately defined microorganisms and well-characterized antigens, allowing accurate determination of immune responses against various antigens of choice.

[0073] The invention is further explained in the experimental part of this description without limiting the invention thereto.

### Description of the Figures

[0074] FIG. 1 illustrates the organization of the cps2 gene cluster of *S. suis* type 2.

(A) Genetic map of the cps2 gene cluster. The shadowed arrows represent potential ORFs. Interrupted ORFs indicate the presence of stop codons or frame-shift mutations. Gene designations are indicated below the ORFs. The closed arrows indicate the position of the potential promoter sequences. I indicates the position of the potential transcription regulator sequence. III indicates the position of the 100-bp repeated sequence.

- (B) Physical map of the *cps2* locus. Restriction sites are as follows: A: *AhaI*; C: *ClaI*; E: *EcoRI*; H: *HindIII*; K: *KpnI*; M: *MluI*; N: *NsiI*; P: *PstI*; S: *SnaBI*; Sa: *SacI*; X: *XbaI*.
- (C) The DNA fragments cloned in the various plasmids.

**[0075]** FIG. 2 illustrates ethidium bromide stained agarose gel showing PCR products obtained with chromosomal DNA of *S. suis* strains belonging to the serotypes 1,2, 1/2, 9 and 14 and *cps2J*, *cpsII*, and *cps9H* primer sets as described herein.

(A) *cpsII* primers; (B) *cps2J* primers and (C) *cps9H* primers.

Lanes 1-3: serotype 1 strains; lanes 4-6: serotype 2 strains; lanes 7-9: serotype 1/2 strains; lanes 10-12: serotype 9 strains and lanes 13-15: serotype 14 strains.

(B) Ethidium bromide stained agarose gel showing PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 2, type 1 or type 9 strains and *cps2J*, *cpsII* and *cpsH* primer sets as described in Materials and Methods. Bacterial DNA suitable for PCR was prepared by using the multiscreen methods as described previously (20).

(C) *cpsII* primers. (B) *cps2J* primers and (C) *cps9H* primers.

Lanes 1-3: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 1 strains; lanes 4-6: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 2 strains; lanes 7-9: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 9 strains; lanes 10-12: PCR products obtained with chromosomal DNA from serotype 9, 2 and 1 strains respectively; lane 13: negative control, no DNA present.

**[0076]** FIG. 3 illustrates the CPS2 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

**[0077]** FIG. 4 illustrates the CPS1 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

**[0078]** FIG. 5 illustrates the CPS9 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

[0079] FIG. 6 illustrates the CPS7 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

[0080] FIG. 7 illustrates alignment of the N-terminal parts of Cps2J and Cps2K.

Identical amino acids are marked by bars. The amino acids shown in bold are also conserved in CPS14I Cps14J of *S. pneumoniae* and several other glycosyltransferases (19). The aspartate residues marked by asterisks are strongly conserved.

[0081] FIG. 8 illustrates transmission electron micrographs of thin sections of various *S. suis* strains.

- (A) wild type strain 10;
- (B) mutant strain l0cpsB;
- (C) mutant strain l0cpsEF.

Bar = 100 nm

[0082] FIG. 9 illustrates the kinetics of phagocytosis of wild type and mutant *S. suis* strains.

(A) Kinetics of phagocytosis of wild type and mutant *S. suis* strains by porcine alveolar macrophages. Phagocytosis was determined as described herein. The Y-axis represents the number of CFU per milliliter in the supernatant fluids as determined by plate counting, the X-axis represents time in minutes.

- wild type strain 10;
- mutant strain l0cpsB;
- Δ mutant strain l0cpsEF.

(B) Kinetics of intracellular killing of wild type and mutant *S. suis* strains by porcine AM. The intracellular killing was determined as described herein. The Y-axis represents the number of CFU per ml in the supernatant fluids after lysis of the macrophages as determined by plate counting, the X-axis represents time in minutes.

- wild type strain 10;
- mutant strain l0cpsB;
- Δ mutant strain l0cpsEF.

[0083] FIG. 10 illustrates the nucleotide sequence alignment of the highly conserved 100-bp repeated element.

- 1) 100-bp repeat between cps2G and cps2H
- 2) 100-bp repeat within "cps2M"
- 3) 100-bp repeat between cps2O and cps2P

[0084] FIG. 11 illustrates the cps2, cps9 and cps7 gene clusters of *S. suis* serotypes 2, 9 and 7.

(A) Genetic organization of the cps2 gene cluster [84]. The large arrows represent potential ORFs. Gene designations are indicated below the ORFs. Identically filled arrows represent ORFs which showed homology. The small closed arrows indicate the position of the potential promoter sequences. | indicates the position of the potential transcription regulator sequence.

(B) Physical map and genetic organization of the cps9 gene cluster [15]. Restriction sites are as follows: B: *Bam*HI; P: *Pst*I; H: *Hind*III; X: *Xba*I. The DNA fragments cloned in the various plasmids are indicated. The open arrows represent potential ORFs.

(C) Physical map and genetic organization of the cps7 gene cluster. Restriction sites are as follows: C: *Clal*; P: *Pst*I; Sc: *Sca*I. The DNA fragments cloned in the various plasmids are indicated. The open arrows represent potential ORFs.

[0085] FIG. 12 illustrates ethidium bromide stained agarose gel showing PCR products.

(A) Ethidium bromide stained agarose gel showing PCR products obtained with chromosomal DNA of *S. suis* strains belonging to the serotypes 1, 2, 9 and 7 and the cps7H primer set. Strain designations are indicated above the lanes. C: negative control, no DNA present. M: molecular size marker (lambda digested with *Eco*RI and *Hind*III).

(B) Ethidium bromide stained agarose gel showing PCR products obtained with serotype 7 strains collected in different countries and from different organs. Bacterial DNA suitable for PCR was prepared by using the multiscreen method as described herein [89]. Strain designations are indicated above the lanes. M: molecular size marker (lambda digested with *Eco*RI and *Hind*III).

## Detailed Description of the Invention

### Experimental part

### MATERIAL AND METHODS

#### Bacterial strains and growth conditions.

[0086] The bacterial strains and plasmids used in this study are listed in Table 1. *S. suis* strains were grown in Todd-Hewitt broth (code CM189, Oxoid), and plated on Columbia agar blood base (code CM331, Oxoid) containing 6% (v/v) horse blood. *E. coli* strains were grown in Luria broth (28) and plated on Luria broth containing 1.5% (w/v) agar. If required, antibiotics were added to the plates at the following concentrations: spectinomycin: 100 ug/ml for *S. suis* and 50 ug/ml for *E. coli* and ampicillin, 50 ug/ml.

[0087] **Serotyping.** The *S. suis* Strains were serotyped by the slide agglutination test with serotype-specific antibodies (44).

[0088] **DNA techniques.** Routine DNA manipulations were performed as described by Sambrook et al. (36).

[0089] **Alkaline phosphatase activity.** To screen for PhoA fusions in *E. coli*, plasmid libraries were constructed. Therefore, chromosomal DNA of *S. suis* type 2 was digested with *AluI*. The 300-500-bp fragments were ligated to *SmaI*-digested pPHOS2. Ligation mixtures were transformed to the PhoA<sup>-</sup> *E. coli* strain CC118. Transformants were plated on LB media supplemented with 5-Bromo-4-chloro-3-indolylfosfaat (BCIP, 50 ug/ml, Boehringer, Mannheim, Germany). Blue colonies were purified on fresh LB/BCIP plates to verify the blue phenotype.

[0090] **DNA sequence analysis.** DNA sequences were determined on a 373A DNA Sequencing System (Applied Biosystems, Warrington, GB). Samples were prepared by using an ABI/PRISM dye terminator cycle sequencing ready reaction kit (Applied Biosystems). Sequencing data were assembled and analyzed using the MacMollyTetra program. Custom-made sequencing primers were purchased from Life Technologies. Hydrophobic stretches within proteins were predicted by the method of Klein et al. (17). The BLAST program available on Netscape Navigator<sup>TM</sup> was used to search for protein sequences related to the deduced amino acid sequences.

**[0091] Construction of gene-specific knock-out mutants of *S. suis*.** To construct the mutant strains 10cpsB and 10cpsEF, we electrotransformed the pathogenic serotype 2 strain 10 (45, 49) of *S. suis* with pCPS11 and pCPS28 respectively. In these plasmids, the *cpsB* and *cpsEF* genes were disturbed by the insertion of a spectinomycin-resistance gene. To create pCPS11, the internal 400 bp *PstI*/*BamHI* fragment of the *cpsB* gene in pCPS7 was replaced by the *Spc<sup>R</sup>* gene. For this purpose, pCPS7 was digested with *PstI* and *BamHI* and ligated to the 1,200-bp *PstI*-*BamHI* fragment, containing the *Spc<sup>R</sup>* gene, from pIC-spc. To construct pCPS28, we have used pIC20R. In this plasmid we inserted the *KpnI*-*Sall* fragment from pCPS17 (resulting in pCPS25) and the *XbaI*-*ClaI* fragment from pCPS20 (resulting in pCPS27). pCPS27 was digested with *PstI* and *XhoI* and ligated to the 1,200-bp *PstI*-*XhoI* fragment, containing the *Spc<sup>R</sup>* gene of pIC-spc. The electrotransformation to *S. suis* was carried out as described before (38).

**[0092] Southern blotting and hybridization.** Chromosomal DNA was isolated as described by Sambrook et al. (36). DNA fragments were separated on 0.8% agarose gels and transferred to Zeta-Probe GT membranes (Bio-Rad) as described by Sambrook et al. (36). DNA probes were labeled with [<sup>32</sup>P] dCTP (3000 Ci mmol<sup>-1</sup>; Amersham) by use of a random primed labeling kit (Boehringer). The DNA on the blots was hybridized at 65°C with appropriate DNA probes as recommended by the supplier of the Zeta-Probe membranes. After hybridization, the membranes were washed twice with a solution of 40 mM sodium phosphate, pH 7.2, 1 mM EDTA, 5% SDS for 30 min at 65°C and twice with a solution of 40 mM sodium phosphate, pH 7.2, 1 mM EDTA, 1% SDS for 30 min at 65°C.

**[0093] PCR.** The primers used in the *cps2J* PCR correspond to the positions 13791-13813 and 14465-14443 in the *S. suis* *cps2* locus. The sequences were: 5'-CAAACGCAAGGAATTACGGTATC-3' (SEQ. ID. No. 1) and 5'-GAGTATCTAAAGAATGCCTATTG-3' (SEQ. ID. No. 2). The primers used for the *cpsII* PCR correspond to the positions 4398-4417 and 4839-4821 in the *S. suis* *cpsI* sequence. The sequences were: 5'-GGCGGTCTAGCAGATGCTCG-3' (SEQ. ID. No. 3) and 5'-GCGAACTGTTAGCAATGAC-3' (SEQ. ID. No. 4). The primers used in the *cps9H* PCR correspond to the positions 4406-4126 and 4494-4475 in the *S. suis* *cps9* sequence. The sequences

were: 5'-GGCTACATATAATGGAAGCCC3' (SEQ. ID No. 5) and 5'-CGGAAGTATCTGGGCTACTG-3' (SEQ. ID. No. 6).

**[0094] Construction of gene-specific knock-out mutants of *S. suis*.** To construct the mutant strains 10cpsB and 10cpsEF, we electrotransformed the pathogenic serotype 2 strain 10 of *S. suis* with pCPS11 and pCPS28 respectively. In these plasmids, the *cpsB* and *cpsEF* genes were disturbed by the insertion of a spectinomycin-resistance gene. To create pCPS11, the internal 400 bp *PstI*-*BamHI* fragment of the *cpsB* gene in pCPS7 was replaced by the  $\text{Spc}^R$  gene. For this purpose, pCPS7 was digested with *PstI* and *BamHI* and ligated to the 1,200-bp *PstI*-*BamHI* fragment, containing the  $\text{Spc}^R$  gene, from pIC-spc. To construct pCPS28, we have used pIC20R. In this plasmid, we inserted the *KpnI*-*Sall* fragment from pCPS17 (resulting in pCPS25) and the *XbaI*-*Clal* fragment from pCPS20 (resulting in pCPS27). pCPS27 was digested with *PstI* and *XhoI* and ligated to the 1,200-bp *PstI*-*XhoI* fragment, containing the  $\text{Spc}^R$  gene of pIC-spc. The electrotransformation to *S. suis* was carried out as described before (38).

**[0095] Phagocytosis assay.** Phagocytosis assays were performed as described by Leij et al. (23). Briefly, to opsonize the cells,  $10^7$  *S. suis* cells were incubated with 6% SPF-pig serum for 30 min at 37°C in a head-over-head rotor at 6 rpm.  $10^7$  AM and  $10^7$  opsonized *S. suis* cells were combined and incubated at 37°C under continuous rotation at 6 rpm. At 0, 30, 60 and 90 min, 1- ml samples were collected and mixed with 4 ml of ice-cold EMEM to stop phagocytosis. Phagocytes were removed by centrifugation for 4 min at 110 x g and 4°C. The number of colony-forming units, ("CFU") in the supernatants was determined. Control experiments were carried out simultaneously by combining  $10^7$  opsonized *S. suis* cells with EMEM (without AM).

**[0096] Killing assays.** AM ( $10^7$ /ml) and opsonized *S. suis* cells ( $10^7$ /ml) were mixed 1 : 1 and incubated for 10 min at 37°C under continuous rotation at 6 rpm. Ice-cold EMEM was added to stop further phagocytosis and killing. To remove extracellular *S. suis* cells, phagocytes were washed twice (4 min, 110 x g, 4°C) and resuspended in 5 ml EMEM containing 6% SPF serum. The tubes were incubated at 37°C under rotation at 6 rpm. After 0, 15, 30, 60 and 90 min, samples were collected and mixed with ice-cold EMEM to stop further killing. The samples were centrifuged for 4 min at 110 x g at 4°C and the phagocytic cells were lysed in EMEM containing



1% saponine for 20 min at room temperature. The number of CFU in the suspensions was determined.

[0097] **Pigs.** Germfree pigs, crossbreeds of Great Yorkshire and Dutch Landrace, were obtained from sows by caesarian sections. The surgery was performed in sterile flexible film isolators. Pigs were allotted to groups, each consisting of 4 pigs, and were housed in sterile stainless steel incubators.

[0098] **Experimental infections.** Pigs were inoculated intranasally with *S. suis* type 2 as described before. To predispose the pigs for infection with *S. suis*, five-day old pigs were inoculated intranasally with about  $10^7$  CFU of *Bordetella bronchiseptica* strain 92932. Two days later, the pigs were inoculated intranasally with *S. suis* type 2 ( $10^6$  CFU). Pigs were monitored twice daily for clinical signs of disease, such as fever, nervous signs and lameness. Blood samples were collected three times a week from each pig. White blood cells were counted with a cell counter. To monitor infection with *S. suis* and *B. bronchiseptica* and to check for absence of contaminants, we collected swabs of nasopharynx and feces daily. The swabs were plated directly onto Columbia agar containing 6% horse blood. After three weeks, the pigs were killed and examined for pathological changes. Tissue specimens from the central nervous system, serosae, and joints were examined bacteriologically and histologically as described herein (45, 49). Colonization of the serosae was scored positively when *S. suis* was isolated from the pericardium, thoracic pleura or the peritoneum. Colonization of the joints was scored positively when *S. suis* was isolated from one or more joints (12 joints per animal were scored).

[0099] **Vaccination and challenge.** One week old pigs were vaccinated intravenously with a dosage of  $10^6$  cfu of the *S. suis* strains 10cpsEF or 10cpsB. Three weeks later, the pigs were challenged intravenously with the pathogenic Serotype 2 strain 10 ( $10^7$  cfu). Disease monitoring, hematological, serological and bacteriological examinations as well as post-mortum examinations were as described before under experimental infections.

[0100] **Electron Microscopy.** Bacteria were prepared for electron microscopy as described by Wagenaar et al. (50). Shortly, bacteria were mixed with agarose MP (Boehringer) of  $37^\circ\text{C}$  to a concentration of 0.7%. The mixture was immediately cooled on ice. Upon gelifying, samples were cut into 1 to 1.5 mm slices and incubated in a fixative containing 0.8%

glutaraldehyde and 0.8% osmiumtetroxide. Subsequently, the samples were fixed and stained with uranyl acetate by microwave stimulation, dehydrated and imbedded in eponaraldite resin. Ultra-thin sections were counterstained with lead citrate and examined with a Philips CM 10 electron microscope at 80 kV (FIG. 8).

**[0101] Isolation of porcine alveolar macrophages (AM).** Porcine AM were obtained from the lungs of specific pathogen free ("SPF") pigs. Lung lavage samples were collected as described by van Leengoed et al. (43). Cells were suspended in EMEM containing 6% (v/v) SPF-pig serum and adjusted to  $10^7$  cells per ml.

## RESULTS

### Identification of the *cps* locus.

**[0102]** The *cps* locus of *S. suis* type 2 was identified through a strategy developed for the genetic identification of exported proteins (13, 31). In this system, we used a plasmid (pPHOS2) containing a truncated alkaline phosphatase gene (13). The gene lacked the promoter sequence, the translational start site and the signal sequence. The truncated gene is preceded by a unique *SmaI* restriction site. Chromosomal DNA of *S. suis* type 2, digested with *AluI*, was randomly cloned in this restriction site. Because translocation of PhoA across the cytoplasmic membrane of *E. coli* is required for enzymatic activity, the system can be used to select for *S. suis* fragments containing a promoter sequence, a translational start site and a functional signal sequence. Among 560 individual *E. coli* clones tested, 16 displayed a dark blue phenotype when plated on media containing BCIP. DNA sequence analysis of the inserts from several of these plasmids was performed (results not shown) and the deduced amino acid sequences were analyzed. The hydrophobicity profile of one of the clones (pPHOS7, results not shown) showed that the N-terminal part of the sequence resembled the characteristics of a typical signal peptide: a short hydrophilic N-terminal region is followed by a hydrophobic region of 38 amino acids. These data indicate that the *phoA* system was successfully used for the selection of *S. suis* genes encoding exported proteins. Moreover, the sequences were analyzed for similarities present in the databases. The sequence of pPHOS7 showed a high similarity (37% identity) with the protein encoded by the *cps14C* gene of *Streptococcus pneumoniae* (19). This strongly suggests that pPHOS7 contains a part of the *cps* operon of *S. suis* type 2.

**[0103] Cloning of the flanking *cps* genes.** In order to clone the flanking *cps* genes of *S. suis* type 2, the insert of pPHOS7 was used as a probe to identify chromosomal DNA fragments which contain flanking *cps* genes. A 6-kb *HindIII* fragment was identified and cloned in pKUN19. This yielded clone pCPS6 (FIG. 1, part C). Sequence analysis of the insert of pCPS6 revealed that pCPS6 most probably contained the 5'-end of the *cps* locus, but still lacked the 3'-end. Therefore, sequences of the 3'-end of pCPS6 were in turn used as a probe to identify chromosomal fragments containing *cps* sequences located further downstream. These fragments were also cloned in pKUN19, resulting in pCPS17. Using the same system of chromosomal walking, we subsequently generated the plasmids pCPS18, pCPS20, pCPS23 and pCPS26, containing downstream *cps* sequences.

**[0104] Analysis of the *cps* operon.** The complete nucleotide sequence of the cloned fragments was determined (FIG. 4). Examination of the compiled sequence revealed the presence of at least 13 potential open reading frames (Orfs), which were designated as Orf 2Y, Orf2X and Cps2A-Cps2K (FIG. 1, part A; FIG. 1, part A). Moreover, a 14th, incomplete Orf (Orf 2Z) was located at the 5'-end of the sequence. Two potential promoter sequences were identified. One was located 313 bp (locations 1885-1865 and 1884-1889) upstream of Orf2X. The other potential promoter sequence was located 68 bp upstream of Orf2Y (locations 2241-2236 and 2216-2211). Orf2Y is expressed in opposite orientation. Between Orfs 2Y and 2Z, the sequence contained a potential stem-loop structure, which could act as a transcription terminator. Each Orf is preceded by a ribosome-binding site and the majority of the Orfs are very closely linked. The only significant intergenic gap was found between Cps2G and Cps2H (389 nucleotides). However, no obvious promoter sequences or potential stem-loop structures were found in this region. These data suggest that Orf2X and Cps2A-Cps2K are arranged as an operon.

**[0105]** An overview of all Orfs with their properties is shown in Table 2. The majority of the predicted gene products is related to proteins involved in polysaccharide biosynthesis. Orf2Z showed some similarity with the YitS protein of *Bacillus subtilis*. YitS was identified during the sequence analysis of the complete genome of *B. subtilis*. The function of the protein is unknown.

[0106] Orf2Y showed similarity with the YcxD protein of *B. subtilis* (53). Based on the similarity between YcxD and MocR of *Rhizobium meliloti* (33), YcxD was suggested to be a regulatory protein.

[0107] Orf2X showed similarity with the hypothetical YAAA proteins of *Haemophilus influenzae* and *E. coli*. The function of these proteins is unknown.

[0108] The gene products encoded by the *cps2A*, *cps2B*, *cps2C* and *cps2D* genes showed approximate similarity with the CpsA, CpsC, CpsD and CpsB proteins of several serotypes of *Streptococcus pneumoniae* (19), respectively. This suggests similar functions for these proteins. Hence, Cps2A may have a role in the regulation of the capsular polysaccharide synthesis. Cps2B and Cps2C could be involved in the chain length determination of the type 2 capsule and Cps2C can play an additional role in the export of the polysaccharide. The Cps2D protein of *S. suis* is related to the CpsB protein of *S. pneumoniae* and to proteins encoded by genes of several other Gram-positive bacteria involved in polysaccharide or exopolysaccharide synthesis, but their function is unknown (19).

[0109] The protein encoded by the *cps2E* gene showed similarity to several bacterial proteins with glycosyltransferase activities Cps14E and Cps19fE of *S. pneumoniae* serotypes 14 and 19F (18, 19, 29), CpsE of *Streptococcus salvarius* (X94980) and CpsD of *Streptococcus agalactiae* (34). Recently, Kolkman et al. (18) showed that Cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier, the first step in the biosynthesis of the *S. pneumoniae* type 14 repeating unit. Based on these data, a similar function may be fulfilled by Cps2E of *S. suis*.

[0110] The protein encoded by the *cps2F* gene showed similarity to the protein encoded by the *rfbU* gene of *Salmonella enteritica*. (25). This similarity is most pronounced in the C-terminal regions of these proteins. The *rfbU* gene was shown to encode mannosyltransferase activity (25).

[0111] The *cps2G* gene encoded a protein that showed moderate similarity with the *rfbF* gene product of *Campylobacter hyoilei* (22), the *epsF* gene product of *S. thermophilus* (40) and the *capM* gene product of *S. aureus* (24). On the basis of similarity, the *rfbF*, *epsF* and *capM*

genes are suggested to encode galactosyltransferase activities. Hence, a similar glycosyltransferase activity could be fulfilled by the *cps2G* gene product.

[0112] The *cps2H* gene encodes a protein that is similar to the N-terminal region of the *lgtD* gene product of *Haemophilus influenzae* (U32768). Moreover, the hydrophobicity plots of Cps2H and LgtD looked very similar in these regions (data not shown). Based on sequence similarity, the *lgtD* gene product was suggested to have glycosyltransferase activity (U32768).

[0113] The gene product encoded by the *cps2I* gene showed some similarity with a protein of *Actinobacillus actinomycetemcomitans* (AB002668). This protein is part of the gene cluster responsible for the serotype-b-specific antigen of *A. actinomycetemcomitans*. The function of the protein is unknown.

[0114] The gene products encoded by the *cps2J* and *cps2K* genes showed significant similarities to the Cps14J protein of *S. pneumoniae*. The *cps14J* gene of *S. pneumoniae* was shown to encode a  $\beta$ -1,4-galactosyltransferase activity. In *S. pneumoniae*, CpsJ is responsible for the addition of the fourth (*i.e.* last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide (20). Even some similarity was found between Cps2J and Cps2K (FIG. 2, 25.5% similarity). This similarity was most pronounced in the N-terminal regions of the proteins (FIG. 7). Recently, two small conserved regions were identified in the N-terminus of Cps14J and Cps14I and their homologues (20). These regions were predicted to be important for catalytic activity. Both regions, DXS and DXDD (FIG. 2), were also found in Cps2J and Cps2K.

[0115] **Distribution of the *cps2* genes in other *S. suis* serotypes.** To examine the relationship between the *cps2* genes and *cps* genes in the other *S. suis* serotypes, we performed crosshybridization experiments. DNA fragments of the individual *cps2* genes were amplified by PCR, labeled with  $^{32}\text{P}$ , and used to probe Southern blots of chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. Large variations in the hybridization patterns were observed (Table 4). As a positive control, we used a probe specific for 16S rRNA. The 16S rRNA probe hybridized with all serotypes tested. However, none of the other genes tested were common in all serotypes. Based on the genetic organization of the genes, we previously suggested that *orfX* and *cpsA-cpsK* genes are part of one operon and that the proteins encoded by these genes are all involved in polysaccharide biosynthesis. OrfY and OrfZ are not a part of this operon, and their

role in the polysaccharide biosynthesis is unclear. Based on sequence similarity data, OrfY may be involved in regulation of the *cps2* genes. OrfZ is proposed to be unrelated to polysaccharide biosynthesis. Probes specific for the *orfZ*, *orfY*, *orfX*, *cpsA*, *cpsB*, *cpsC* and *cpsD* genes hybridized with most other serotypes. This suggests that the proteins encoded by these genes are not type-specific, but may perform more common functions in biosynthesis of the capsular polysaccharide. This confirms previous data which showed that the *cps2A-cps2D* genes showed strong similarity to *cps* genes of several serotypes of *Streptococcus pneumoniae*. Based on this similarity, Cps2A is possibly a regulatory protein, whereas Cps2B and Cps2C may play a role in length determination and export of polysaccharide. The *cps2E* gene hybridized with DNA of Serotypes 1, 2, 14 and 1/2. The *cps2E* gene showed a strong similarity to the *cps14E* gene of *S. pneumoniae* (18). This enzyme was shown to have a glucosyl-1-phosphate activity and catalyzed the transfer of glucose to a lipid carrier (18). These data indicate that a glycosyltransferase closely related to Cps14E may be responsible for the first step in the biosynthesis of polysaccharide in the *S. suis* serotypes 1, 2, 14 and 1/2. The *cps2F*, *cps2G*, *cps2H*, *cps2I* and *cps2J* genes hybridized with chromosomal DNA of serotypes 2 and 1/2 only. The *cps2G* gene showed an additional weak hybridization signal with DNA of serotype 34. In agglutination tests, serotype 1/2 showed agglutination with sera specific for serotype 2 as well as with sera specific for serotype 1. This suggests that serotype 1/2 shares antigenic determinants with both types 1 and 2. The hybridization data confirmed these data. All putative glycosyltransferases present in serotype 2 are also present in serotype 1/2. The *cps2K* gene showed a hybridization pattern similar to the *cps2E* gene. Hybridization was observed with DNA of serotypes 1, 2, 14 and 1/2. Taken together, these hybridization data show that the *cps2* gene cluster can be divided into three regions: a central region containing the type-specific genes is flanked by two regions containing common genes for various serotypes.

**[0116] Cloning of the type-specific *cps* genes of serotypes 1 and 9.** To clone the type-specific *cps* genes of *S. suis* serotype 1, we used the *cps2E* gene as a probe to identify chromosomal DNA fragments of type 1 which contain flanking *cps* genes. A 5 kb *EcoRV* fragment was identified and cloned in pKUN19. This yielded pCPS1-1 (FIG. 1, part B). This fragment was in turn used as a probe to identify an overlapping 2.2 kb *HindIII* fragment. pKUN19 containing this *HindIII* fragment was designated pCPS1-2. The same strategy was followed to identify and

clone the type-specific *cps* genes of serotype 9. In this case, we used the *cps2D* gene as a probe. A 0.8 kb HindIII-XbaI fragment was identified and cloned, yielding pCPS9-1 (FIG. 1, part C). This fragment was in turn used as a probe to identify a 4 kb XbaI fragment. pKUN19 containing this 4 kb XbaI fragment was designated pCPS9-2.

**[0117] Analysis of the cloned *cpsI* genes.** The complete nucleotide sequence of the inserts of pCPS1-1 and pCPS1-2 was determined (FIG. 5). Examination of the sequence revealed the presence of five complete and two incomplete Orfs (FIG.1, part B). Each Orf is preceded by a ribosome-binding site. In accord with data obtained for the *cps2* genes of serotype 2, the majority of the Orfs is very closely linked. The only significant gap (718 bp) was found between Cps1G and Cps1H. No obvious promoter sequences or potential stem-loop structures could be found in this region. This suggests that, as in serotype 2, the *cps* genes in serotype 1 are arranged in an operon.

**[0118]** An overview of the Orfs and their properties is shown in Table 2. As expected on the basis of the hybridization data (Table 4), the protein encoded by the *cps1E* gene was related to Cps2E of *S. suis* type 2 (identity of 86%). The fragment cloned in pCPS1-1 lacked the coding region for the first 7 amino acids of the *cps1E* gene.

**[0119]** The protein encoded by the *cps1F* and *cps1G* genes showed strong similarity to the Cps14F and Cps14G proteins of *Streptococcus pneumoniae* serotype 14, respectively (20). The function of the Cps14F is not completely clear, but it has been suggested that Cps14F has a role in glycosyltransferase activity. The *cps14G* gene of *S. pneumoniae* was shown to encode  $\beta$ -1, 4-galactosyltransferase activity. In *S. pneumoniae* type 14, this activity is required for the second step in the biosynthesis of the oligosaccharide subunit (20). Based on the similarity of the data, similar glycosyltransferase and enhancing activities are suggested for the *cps1G* and *cps1F* genes of *S. suis* type 1.

**[0120]** The protein encoded by the *cps1H* gene showed similarity to the Cps14M protein of *S. pneumoniae* (20). Based on sequence similarity, Cps14H was proposed to be the polysaccharide polymerase (20).

**[0121]** The protein encoded by the *cps1I* gene showed some similarity with the Cps14J protein of *S. pneumoniae* (19). The *cps14J* gene was shown to encode a  $\beta$ -1, 4-

galactosyltransferase activity, responsible for the addition of the fourth (*i.e.* last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide.

[0122] Between Cps1G and Cps1H, a gap of 718 bp was found. This region revealed three small Orfs. The three Orfs were expressed in three different reading frames and were not preceded by potential ribosome binding sites, nor contained potential start sites. However, the three potential gene products encoded by this region showed some similarity with three successive regions of the C-terminal part of the EpsK protein of *Streptococcus thermophilus* (27% identity, 40). The region related to the first 82 amino acids is lacking.

[0123] **Analysis of the cloned *cps9* genes.** We also determined the complete nucleotide sequence of the inserts of pCPS9-1 and pCPS9-2 (FIG. 6). Examination of the sequence revealed the presence of three complete and two incomplete Orfs (FIG. 1, part C). As in serotypes 1 and 2, all Orfs are preceded by a ribosome-binding site and are very closely coupled. As suggested by the hybridization data (Table 4), the Cps2D and Cps9D proteins were highly related (Table 2). Based on sequence comparisons, pCPS9-1 lacked the first 27 amino acids of the Cps9D protein.

[0124] The protein encoded by the *cps9E* gene showed some similarity with the CapD protein of *Staphylococcus aureus* serotype 1 (24). Based on sequence similarity data, the Cap1D protein was suggested to be an epimerase or a dehydratase involved in the synthesis of N-acetylfructosamine or N-acetylgalactosamine (63).

[0125] Cps9F showed some similarity to the CapM proteins of *S. aureus* serotypes 5 and 8 (61, 64, 65). Based on sequence similarity data, Cap5M and Cap8M are proposed to be glycosyltransferases (63).

[0126] The protein encoded by the *cps9G* gene showed some similarity to a protein of *Actinobacillus actinomycetemcomitans* (AB002668\_4). This protein is part of a gene cluster responsible for the serotype-b specific antigens of *Actinobacillus actinomycetemcomitans*. The function of the protein is unknown.

[0127] The protein encoded by the *cps9H* gene showed some similarity to the *rfbB* gene of *Yersinia enterocolitica* (68). The RfbB protein was shown to be essential for O-antigen synthesis, but the function of the protein in the synthesis of the 0:3 lipopolysaccharide is unknown.



[0128] **Serotype 1 and serotype 9 specific *cps* genes.** To determine whether the cloned fragments in pCPS1-1, pCPS1-2, pCPS9-1 and pCPS9-2 contained the type-specific genes for serotype 1 and 9, respectively, cross-hybridization experiments were performed. DNA fragments of the individual *cps1* and *cps9* genes were amplified by PCR, labeled with  $^{32}\text{P}$ , and used to probe Southern blots of chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. The results are shown in Table 5. Based on the data obtained with the *cps2E* probe (Table 4), the *cps1E* probe was expected to hybridize with chromosomal DNA of *S. suis* serotypes 1, 2, 14, 27 and 1/2. The *cps1H*, *cps9E* and *cps9F* probes hybridized with most other serotypes. However, the *cps1F* and *cps1G* and *cps1I* probes hybridized with chromosomal DNA of serotypes 1 and 14 only. The *cps9G* and *cps9H* probes hybridized with serotype 9 only. These data suggest that the *cps9G* and *cps9H* probes are specific for serotype 9 and, therefore, could be useful tools for the development of rapid and sensitive diagnostic tests for *S. suis* type 9 infections.

[0129] **Type specific PCR.** So far, the probes were tested on the 35 different reference strains only. To test the diagnostic value of the typespecific *CpS* probes further, several other *S. suis* serotype 1, 2, 1/2, 9 and 14 strains were used. Moreover, since a PCR-based method would be even more rapid and sensitive than a hybridization test, we tested whether we could use a PCR for the serotyping of the *S. suis* strains. The oligonucleotide primer sets were chosen within the *cps2J*, *cps1I* and *cps9H* genes. Amplified fragments of 675 bp, 380 bp and 390 bp were expected, respectively. The results show that 675 bp fragments were amplified on type 2 and 1/2 strains using *cps2J* primers; 380 bp fragments were amplified on type 1 and 14 strains using *cps1I* primers and 390 bp fragments were amplified on type 9 strains using *cps9H* primers.

[0130] **Construction of mutants impaired in capsule production.** To evaluate the role of the capsule of *S. suis* type 2 in pathogenesis, we constructed two isogenic mutants in which capsule production was disturbed. To construct mutant 10cpsB, pCPS11 was used. In this plasmid, a part of the *cps2B* gene was replaced by the spectinomycin-resistance gene. To construct mutant strain 10cpsEF, the plasmid pCPS28 was used. In pCPS28, the 3'-end of *cps2E* gene, as well as the 5'-end, of *cps2F* gene, were replaced by the spectinomycin-resistance gene. pCPS11 and pCPS28 were used to electrotransform strain 10 of *S. suis* type 2 and spectinomycin-resistant colonies were selected. Southern blotting and hybridization experiments were used to

select double crossover integration events (results not shown). To test whether the capsular structure of the strains 10cpsB and 10cpsEF was disturbed, we used a slide agglutination test using a suspension of the mutant strains in hyperimmune anti-*S. suis* type 2 serum (44). The results showed that even in the absence of serotype specific antisera, the bacteria agglutinated. This indicates that, in the mutant strains, the capsular structure was disturbed. To confirm this, thin sections of wild type and mutant strains were compared by electron microscopy. The results showed that, compared to the wild type (FIG. 3, part A), the amount of capsule produced by the mutant strains was greatly reduced (FIG. 3, part B and part C). Almost no capsular material could be detected on the surface of the mutant strains.

**[0131] Capsular mutants are sensitive to phagocytosis and killing by porcine alveolar macrophages ("PAM").** The capsular mutants were tested for their ability to resist phagocytosis by PAM in the presence of porcine SPF serum. The wild type strain 10 seemed to be resistant to phagocytosis under these conditions (FIGs. 9A and 9B). In contrast, the mutant strains were efficiently ingested by macrophages (FIGs. 9A and 9B). After 90 min., more than 99.7% (strain 10cpsB) and 99.8% (strain 10cpsEF) of the mutant cells were ingested by the macrophages. Moreover, as shown in FIGs. 9A and 9B the ingested strains were efficiently killed by the macrophages. 90-98% of all ingested cells were killed within 90 min. No differences could be observed between wild type and mutant strains. These data indicate that the capsule of *S. suis* type 2 efficiently protects the organism from uptake by macrophages *in vitro*.

**[0132] Capsular mutants are less virulent for germfree piglets.** The virulence properties of the wild-type and mutant strains were tested after experimental infection of newborn germfree pigs (45, 49). Table 1 shows that specific and nonspecific signs of disease could be observed in all pigs inoculated with the wild type strain. Moreover, all pigs inoculated with the wild type strain died during the course of the experiment or were killed because of serious illness or nervous disorders (Table 3). In contrast, the pigs inoculated with strains 10cpsB and 10cpsEF showed no specific signs of disease and all pigs survived until the end of the experiment (Table 6). The temperature of the pigs inoculated with the wild type strain increased 2 days after inoculation and remained high until day 5 (Table 3). The temperature of the pigs inoculated with the mutant strains sometimes exceeded 40°C, however, we could observe significant differences in the fever

index (*i.e.* percent of observations in an experimental group during which pigs showed fever ( $>40^{\circ}\text{C}$ )) between pigs inoculated with wild type and mutant strains. All pigs showed increased numbers of polymorphonuclear leucocytes (PMLs) ( $>10 \times 10^9$  PMLs per litre) (Table 3). However, in pigs inoculated with the mutant strains, the percentage of samples with increased numbers of PMLs was considerably lower. *S. suis* strains and *B. bronchiseptica* could be isolated from the nasopharynx and feces swab samples of all pigs from 1 day post-infection until the end of the experiment (Table 3). Postmortem, the wild type strain could frequently be isolated from the central nervous system ("CNS"), kidney, heart, liver, spleen, serosae, joints and tonsils. Mutant strains could easily be recovered from the tonsils, but were never recovered from the kidney, liver or spleen. Interestingly, low numbers of the mutant strains were isolated from the CNS, the serosae, the joints, the lungs and the heart. Taken together, these data strongly indicated that mutant *S. suis* strains, impaired in capsule production, are not virulent for young germfree pigs.

[0133] We describe the identification and the molecular characterization of the *cps* locus, involved in the capsular polysaccharide biosynthesis, of *S. suis*. Most of the genes seemed to belong to a single transcriptional unit, suggesting a coordinate control of these genes. We assigned functions to most of the gene products. We thereby identified regions involved in regulation (Cps2A), chain length determination (Cps2B, C), export (Cps2C) and biosynthesis (Cps2E, F, G, H, J, K). The region involved in biosynthesis is located at the center of the gene cluster and is flanked by two regions containing genes with more common functions. The incomplete *orf2Z* gene was located at the 5'-end of the cloned fragment. Orf2Z showed some similarity with the YitS protein of *B. subtilis*. However, because the function of the YitS protein is unknown, this did not give us any information about the possible function of Orf2Z. Because the *orf2Z* gene is not a part of the *cps* operon, a role of this gene in polysaccharide biosynthesis is not expected. The Orf2Y protein showed some similarity with the YcxD protein of *B. subtilis* (53). The YcxD protein was suggested to be a regulatory protein. Similarly, Orf2Y may be involved in the regulation of polysaccharide biosynthesis. The Orf2X protein showed similarity with the YAAA proteins of *H. influenzae* and *E. coli*. The function of these proteins is unknown. In *S. suis* type 2, the *orf2X* gene seemed to be the first gene in the *cps2* operon. This suggests a role of Orf2X in the polysaccharide biosynthesis. In *H. influenzae* and *E. coli*, however, these proteins

are not associated with capsular gene clusters. The analysis of isogenic mutants impaired in the expression of Orf2X should give more insight in the presumed role of Orf2X in the polysaccharide biosynthesis of *S. suis* type 2.

[0134] The gene products encoded by the *cps2E*, *cps2F*, *cps2G*, *cps2H*, *cps2J* and *cps2K* genes showed little similarity with glycosyltransferases of several Gram-positive or Gram-negative bacteria (18, 19, 20, 22, 25). The *cps2E* gene product shows some similarity with the Cps14E protein of *S. pneumoniae* (18, 19). Cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier (18). In *S. pneumoniae*, this is the first step in the biosynthesis of the oligosaccharide repeating unit. The structure of the *S. suis* serotype 2 capsule contains glucose, galactose, rhamnose, N-acetyl glucosamine and sialic acid in a ratio of 3:1:1:1:1 (7). Based on these data, we conclude that Cps2E of *S. suis* has glycosyltransferase activity and is involved in the linkage of the first sugar to the lipid carrier.

[0135] The C-terminal region of the *cps2F* gene product showed some similarity with the RfbU of *Salmonella enteritica*. RfbU was shown to have mannosyltransferase activity (24). Because mannosyl is not a component of the *S. suis* type 2 polysaccharide, a mannosyltransferase activity is not expected in this organism. Nevertheless, *cps2F* encodes a glycosyltransferase with another sugar specificity.

[0136] Cps2G showed moderate similarity to a family of gene products suggested to encode galactosyltransferase activities (22, 24, 40). Hence, a similar activity is shown for Cps2G.

[0137] Cps2H showed some similarity with LgtD of *H. influenzae* (U32768). Because LgtD was proposed to have glycosyltransferase activity, a similar activity is fulfilled by Cps2H.

[0138] Cps2J and Cps2K showed similarity to Cps14J of *S. pneumoniae* (20). Cps2J showed similarity with Cps14I of *S. pneumoniae* as well. Cps14I was shown to have N-acetyl glucosaminyltransferase activity, whereas Cps14J has a  $\beta$ -1, 4-galactosyltransferase activity (20). In *S. pneumoniae*, Cps14I is responsible for the addition of the third sugar and Cps14J for the addition of the last sugar in the synthesis of the type 14 repeating unit (20). Because the capsule of *S. suis* type 2 contains galactose as well as N-acetyl glucosamine components, galactosyltransferase as well as N-acetyl glucosaminyltransferase activities could be envisaged for the *cps2J* and *cps2K* gene products, respectively. As was observed for Cps14I and Cps14J, the N-

termini of Cps2J and Cps2K showed a significant degree of sequence similarity. Within the N-terminal domains of Cps14I and Cps14J, two small regions were identified, which were also conserved in several other glycosyltransferases (22). Within these two regions, two Asp residues were proposed to be important for catalytic activity. The two conserved regions, DXS and DXDD, were also found in Cps2J and Cps2K.

[0139] The function of Cps2I remains unclear. Cps2I showed some similarity with a protein of *A. actinomycetemcomitans*. Although this protein part is of the gene cluster responsible for the serotype-B-specific antigens, the function of the protein is unknown.

[0140] We further describe the identification and characterization of the *cps* genes specific for *S. suis* serotypes 1, 2 and 9. After the entire *cps2* locus of *S. suis* serotype 2 was cloned and characterized, functions for most of the *cps2* gene products could be assigned by sequence homologies. Based on these data, the glycosyltransferase activities, required for type specificity, could be located in the center of the operon. Cross-hybridization experiments, using the individual *cps2* genes as probes on chromosomal DNAs of the 35 different serotypes, confirmed this idea. The regions containing the type-specific genes of serotypes 1 and 9 could be cloned and characterized, showing that an identical genetic organization of the *CpS* operons of other *S. suis* serotypes exists. The *cps1E*, *cps1F*, *cps1G*, *cps1H*, and *cps1I* genes revealed a striking similarity with *cps14E*, *cps14F*, *cps14G*, *cps14H* and *cps14J* genes of *S. pneumoniae*. Interestingly, *S. pneumoniae* serotype 14 is the serotype most commonly associated with pneumococcal infections in young children (54), whereas *S. suis* serotype 1 strains are most commonly isolated from piglets younger than 8 weeks (46). In *S. pneumoniae*, the *cps14E*, *cps14G*, *cps14I* and *cps14J* encode the glycosyltransferases required for the synthesis of the type 14 tetrameric repeating unit, showing that the *cps1E*, *cps1G* and *cps1I* genes encoded glycosyltransferases. The precise functions of these genes as well as the substrate specificities of the enzymes can be established. In *S. pneumoniae*, the *cps14E* gene was shown to encode a glucosyl-1-phosphate transferase catalyzing the transfer of glucose to a lipid carrier. Moreover, *cpsE*-like genes were found in *S. pneumoniae* serotypes 9N, 13, 14, 15B, 15C, 18F, 18A and 19F (60). *CpsE* mutants were constructed in the serotypes 9N, 13, 14 and 15B. All mutant strains lacked glucosyltransferase activity (60). Moreover, in all these *S. pneumoniae* serotypes, the *cpsE*

gene seemed to be responsible for the addition of glucose to the lipid carrier. Based on these data, we suggest that in *S. suis* type 1, the *cpsIE* gene may fulfil a similar function. The structure of the *S. suis* type 1 capsule is unknown, but it is composed of glucose, galactose, N-acetyl glucosamine, N-acetyl galactosamine and sialic acid in a ratio of 1: 2.4: 1: 1:1.4 (5). Therefore, a role of a *cpsE*-like glucosyltransferase activity can easily be envisaged. *CpsE*-like sequences were also found in serotypes 2, 1/2 and 14.

[0141] For polysaccharide biosynthesis in *S. pneumoniae* type 14, transfer of the second sugar of the repeating unit to the first lipid-linked sugar is performed by the gene products of *cps14F* and *cps14G* (20). Similar to Cps14F and Cps14G, the *S. suis* type 1 proteins Cps1F and Cps1G may act as one glycosyltransferase performing the same reaction. Cps14F and Cps14G of *S. pneumoniae* showed similarity to the N-terminal half and C-terminal half of the SpsK protein of *Sphingomonas* (20, 67), respectively. This suggests a combined function for both proteins. Moreover, *cps14F*- and *cps14G*-like sequences were found in several serotypes of *S. pneumoniae* and these genes always seemed to exist together (60). The same was observed for *S. suis* type 1. The *cps1F* and *cps1G* probes hybridized with type 1 and type 14 strains.

[0142] According to the similarity found between the *cps1H* gene and the *cps14H* gene of *S. pneumoniae* (20), *cps1H* is expected to encode a polysaccharide polymerase.

[0143] The protein encoded by the *cps1I* gene showed some similarity with the Cps14J protein of *S. pneumoniae* (19). The *cps14J* gene was shown to encode a  $\beta$ -1, 4-galactosyltransferase activity, responsible for the addition of the fourth (*i.e.* last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide. In *S. suis* type 2, the proteins encoded by the *cps2J* and *cps2K* genes showed similarity to the Cps14J protein. However, no significant homologies were found between Cps2J, Cps2K and Cps1I. In the N-terminal regions of Cps14J and Cps14I, two small conserved regions, DXS and DXDD, were identified (19). These regions seemed to be important for catalytic activity (13). At the same positions in the sequence, Cps2I contained the regions DXS and DXED.

[0144] In the region between Cps1G and Cps1H, three small Orfs were identified. Since the Orfs were expressed in three different reading frames, and did not contain potential start sites, expression is not expected. However, the three potential gene products encoded by this

region showed some similarity with three successive regions of the C-terminal part of the EpsK protein of *Streptococcus thermophilus* (27% identity, 40). The region related to the first 82 amino acids is lacking. The EpsK protein was suggested to play a role in the export of the exopolysaccharide by rendering the polymerized exopolysaccharide more hydrophobic through a lipid modification. These data could suggest that the sequences in the region between Cps1G and Cps1H originated from epsK-like sequence. Hybridization experiments showed that this *epsK*-like region is also present in other serotype 1 strains as well as in serotype 14 strains (results not shown).

[0145] The function of most of the cloned serotype 9 genes can be established. Based on sequence similarity data, the *cps9E* and *cps9F* genes could be glycosyltransferases (61, 24, 63, 64, 65). Moreover, the *cps9G* and *cps9H* genes showed similarity to genes located in regions involved in polysaccharide biosynthesis, but the function of these genes is unknown (68).

[0146] Cross-hybridization experiments using the individual *cps2*, *cps1* and *cps9* genes as probes showed that the *cps9G* and *cps9H* probes specifically hybridized with serotype 9 strains.

[0147] Therefore, these are useful as tools for the identification of *S. suis* type 9 strains both for diagnostic purposes as well as in epidemiological and transmission studies. We previously developed a PCR method which can be used to detect *S. suis* strains in nasal and tonsil swabs of pigs (62). The method was used to identify pathogenic (EF-positive) strains of *S. suis* serotype 2. Besides *S. suis* type 2 strains, serotype 9 strains are frequently isolated from organs of diseased pigs. However, until now, a rapid and sensitive diagnostic test was not available for type 9 strains. Therefore, the type 9 specific probes or the type 9 specific PCR is of great diagnostic value. The *cps1F*, *cps1G* and *cps1I* probes hybridized with serotype 1 as well as with serotype 14 strains. In coagglutination tests, type 1 strains react with the anti-type 1 as well as with the anti-type 14 antisera (56). This suggests the presence of common epitopes between these serotypes. On the other hand, type 1 strains agglutinated only with anti-type 1 serum (56, 57), indicating that it is possible to detect differences between those serotypes.

[0148] The *cps2F*, *cps2G*, *cps2H*, *cps2I* and *cps2J* probes hybridized with serotypes 2 and 1/2 only. Serotype 34 showed a weak hybridizing signal with the *cps2G* probe. As shown in agglutination tests, type 1/2 strains react with sera directed against type 1 as well as with sera

directed against type 2 strains (46). Therefore, type 1/2 shared antigens with both types 1 and 2. Based on the hybridization patterns of serotype 1/2 strains with the *cps1* and *cps2* specific genes, serotype 1/2 seemed to be more closely related to type 2 strains than to type 1 strains. In our current studies, we identify type-specific genes, primers or probes which are used for the discrimination of serotypes 1, 14 and 2 and 1/2 and others of the 35 serotypes yet known. Furthermore, type-specific genes, primers or probes can now easily be developed for yet unknown serotypes, once they become isolated.

### **Cloning and characterization of a further part of the *cps2* locus.**

[0149] Based on the established sequence, 11 genes, designated *cps2L* to *cps2T*, *orf2U* and *orf2V*, were identified. A gene homologous to genes involved in the polymerization of the repeating oligosaccharide unit (*cps2O*) as well as genes involved in the synthesis of sialic acid (*cps2P* to *cps2T*) were identified. Moreover, hybridization experiments showed that the genes involved in the sialic acid synthesis are present in *S. suis* serotypes 1, 2, 14, 27 and 1/2. The “*cps2M*” and “*cps2N*” regions showed similarity to proteins involved in the polysaccharide biosynthesis of other Gram-positive bacteria. However, these regions seemed to be truncated or were nonfunctional as the result of frame-shift or point mutations. At its 3' -end, the *cps2* locus contained two insertional elements (“*orf2U*” and “*orf2V*”), both of which seemed to be non-functional.

[0150] To clone the remaining part of the *cps2* locus, sequences of the 3'-end of pCPS26 (FIG. 1, part C) were used to identify a chromosomal fragment containing *cps2* sequences located further downstream. This fragment was cloned in pKUN19, resulting in pCPS29. Using a similar approach, we subsequently isolated the plasmids pCPS30 and pCPS34 containing downstream *cps2* sequences (FIG. 1, part C).

### **Analysis of the *cps2* operon.**

[0151] The complete nucleotide sequence of the cloned fragments was determined. Examination of the compiled sequence revealed the presence of: a sequence encoding the C-terminal part of Cps2K, six apparently functional genes (designated *cps2O*-*cps2T*) and the



remnants of 5 different ancestral genes (designated “cps2L”, “cps2M”, “cps2N”, “orf2U” and “orf2V”). The latter genes seemed to be truncated or incomplete as the result of the presence of stop codons or frame-shift mutations (FIG. 1, part A). Neither potential promoter sequences nor potential stem-loop structures could be identified within the sequenced region. A ribosome-binding site precedes each ORF and the majority of the ORFs are very closely linked. Three intergenic gaps were found: one between “cps2M” and “cps2N” (176 nucleotides), one between cps2O and cps2P (525 nucleotides), and one between cps2T and “orf2U” (200 nucleotides). These and our above data show that Orf2X and Cps2A-Orf2T are part of a single operon.

[0152] A list of all loci and their properties is shown in Table 4. The “cps2L” region contained three potential ORFs of 103, 79 and 152 amino acids, respectively, which were only separated from each other by stop codons. Only the first ORF is preceded by a potential ribosomal binding site and contained a methionine start codon. This suggests that “cps2L” originates from an ancestral cps2L gene, which coded for a protein of 339 amino acids. The function of this hypothetical Cps2L protein remains unclear so far: no significant homologies were found between Cps2L and proteins present in the data libraries. It is not clear whether the first ORF of the “cps2L” region is expressed into a protein of 103 amino acids. The “cps2M” region showed homology to the N-terminal 134 amino acids of the NeuA proteins of *Streptococcus agalactiae* and *Escherichia coli* (AB017355, 32). However, although the “cps2 M” region contained a potential ribosome binding site, a methionine start codon was absent. Compared with the *S. agalactiae* sequence, the ATG start codon was replaced by a lysin encoding AAG codon. Moreover, the region homologous to the first 58 amino acids of the *S. agalactiae* NeuA (identity 77%) was separated from the region homologous to amino acids 59-134 of NeuA by a repeated DNA sequence of 100-bp (*see*, herein). In addition, the region homologous to amino acids 59 to 95 of NeuA (identity 32%) and the region homologous to the amino acids 96 to 134 of NeuA (identity 50%) were present in different reading frames. Therefore, the partial and truncated NeuA homologue is probably nonfunctional in *S. suis*. The “cps2N” region showed homology to CpsJ of *S. agalactiae* (accession no. AB017355). However, sequences homologous to the first 88 amino acids of CpsJ were lacking in *S. suis*. Moreover, the homologous region was present in two different reading frames. The protein encoded by the cps2O gene showed homology to proteins of

several streptococci involved in the transport of the oligosaccharide repeating unit (accession no. AB017355), suggesting a similar function for Cps2O. The proteins encoded by the cps2P, cps2S and cps2T genes showed homology to the NeuB, NeuD and NeuA proteins of *S. agalactiae* and *E. coli* (accession no. AB017355). Because the “cps2M” region also showed homology to NeuA of *E. coli*, the *S. suis* cps2 locus contains a functional neuA gene (cps2T) as well as a nonfunctional (“cps2M”) gene. The mutual homology between these two regions showed an identity of 77% at the amino acid level over amino acids 1-58 and 49% over the amino acids 59-134. Cps2Q and Cps2R showed homology to the N-terminal and C-terminal parts of the NeuC protein of *S. agalactiae* and *E. coli*, respectively. This suggests that the function of the *S. agalactiae* NeuC protein in *S. suis* is likely fulfilled by two different proteins. In *E. coli*, the neu genes are known to be involved in the synthesis of sialic acid. NeuNAc is synthesized from N-acetylmannosamine and phosphoenolpyruvate by NeuNAc synthetase. Subsequently, NeuNAc is converted to CMP-NeuNAc by the enzyme CMP-NeuNAc synthetase. CMP-NeuNAc is the substrate for the synthesis of polysaccharide. In *E. coli*, K1 NeuB is the NeuNAc synthetase, and NeuA is the CMP-NeuNAc synthetase. NeuC has been implicated in the NeuNAc synthesis, but its precise role is not known. The precise role of NeuD is not known. A role of the Cps2P-Cps2T proteins in the synthesis of sialic acid can easily be envisaged, since the capsule of *S. suis* serotype 2 is rich in sialic acid. In *S. agalactiae*, sialic acid has been shown to be critical to the virulence function of the type III capsule. Moreover, it has been suggested that the presence of sialic acid in the capsule of bacteria which can cause meningitis may be important for these bacteria to breach the blood-brain barrier. So far, however, the requirement of the sialic acid for virulence of *S. suis* remains unclear.

[0153] “Orf2U” and “Orf2V” showed homology to proteins located on two different insertional elements. “Orf2U” is homologous to IS1194 of *Streptococcus thermophilus*, whereas “Orf2V” showed homology to a putative transposase of *Streptococcus pneumoniae*. This putative transposase was recently found to be associated with the type 2 capsular locus of *S. pneumoniae*. Compared with the original insertional elements in *S. thermophilus* and *S. pneumoniae*, both “Orf2U” and “Orf2V” are likely to be nonfunctional due to frame shift mutations within their coding regions.

[0154] A striking observation was the presence of a sequence of 100 bp (FIG. 10) which was repeated three times within the *cps2* operon. The sequence is highly conserved (between 94% and 98%) and was found in the intergenic regions between *cps2G* and *cps2H*, within “*cps2M*” and between *cps2O* and *cps2P*. No significant homologies were found between this 100-bp direct repeat sequence and sequences present in the data libraries, suggesting that the sequence is unique for *S. suis*.

#### **Distribution of the *cps2* sequences among the 35 *S. suis* serotypes.**

[0155] To examine the presence of sialic acid encoding genes in other *S. suis* serotypes, we performed cross-hybridization experiments. DNA fragments of the individual *cps2* genes were amplified by PCR, radiolabeled with <sup>32</sup>P and hybridized to chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. As a positive control, we used a probe specific for *S. suis* 16S rRNA. The 16S rRNA probe hybridized with almost equal intensities to all serotypes tested (Table 4). The “*cps2L*” sequence hybridized with DNA of serotypes 1, 2, 14 and 1/2. The “*cps2M*”, *cps2O*, *cps2P*, *cps2Q*, *cps2R*, *cps2S* and *cps2T* genes hybridized with DNA of serotypes 1, 2, 14, 27 and 1/2. Because the *cps2P*-*cps2T* genes are most likely involved in the synthesis of sialic acid, these results suggest that sialic acid is also a part of the capsule in the *S. suis* serotypes 1, 2, 14, 27 and 1/2. This is in agreement with the finding that the serotypes 1, 2 and 1/2 possess a capsule that is rich in sialic acid. Although the chemical compositions of the capsules of serotypes 14 and 27 are unknown, recent agglutination studies using sialic acid-binding lectins suggested the presence of sialic acid in *S. suis* serotype 14, but not in serotype 27. In these studies, sialic acid was also detected in serotypes 15 and 16. Since the latter observation is not in agreement with our hybridization studies, it might be that other genes, not homologous to the *cps2P*-*cps2T* genes, are responsible for the sialic acid synthesis in serotypes 15 and 16.

[0156] A probe based on “*cps2N*” sequences hybridized with DNA from serotypes 1, 2, 14 and 1/2. A probe specific for “*orf2U*” hybridized with serotypes 1, 2, 7, 14, 24, 27, 32, 34, and 1/2, whereas a probe specific for “*orf2V*” hybridized with many different serotypes. In addition, we prepared a probe specific for the 100-bp direct repeat sequence. This probe hybridized with the serotypes 1, 2, 13, 14, 22, 24, 27, 29, 32, 34 and 1/2 (Table 4). To analyze the

number of copies of the direct repeat sequence within the *S. suis* serotype 2 chromosome, a Southern blot hybridization and analysis was performed. Therefore, chromosomal DNA of *S. suis* serotype 2 was digested with NcoI and hybridized with a <sup>32</sup>P-labeled direct repeat sequence. Only one hybridizing fragment, containing the three direct repeats present on the *cps2* locus, was found (results not shown). This indicates that the 100-bp direct repeat sequence is only associated with the *cps2* locus. In *S. pneumoniae*, a 115-bp long repeated sequence was found to be associated with the capsular genes of serotypes 1, 3, 14 and 19F. In *S. pneumoniae*, this 115-bp sequence was also found in the vicinity of other genes involved in pneumococcal virulence (hyaluronidase and neuraminidase genes). A regulatory role of the 115-bp sequence in coordinate control of these virulence-related genes was suggested.

[0157] To study the role of the capsule in resistance to phagocytosis and in virulence, we constructed two isogenic mutants in which capsule synthesis was disturbed. In 10cpsB, the *cps2B* gene was disturbed by the insertion of an antibiotic-resistance gene, whereas in 10cpsEF, parts of the *cps2E* and *cps2F* genes were replaced. Both mutant strains seemed to be completely unencapsulated. Because the *cps2* genes seemed to be part of an operon, polar effects cannot be excluded. Therefore, these data did not give any information about the role of Cps2B, Cps2E or Cps2F in the polysaccharide biosynthesis. However, the results clearly show that the capsular polysaccharide of *S. suis* type 2 is a surface component with antiphagocytic activity. *In vitro* wild type encapsulated bacteria are ingested by phagocytes at a very low frequency, whereas the mutant unencapsulated bacteria are efficiently ingested by porcine macrophages. Within 2 hours, over 99.6% of mutant bacteria were ingested and over 92% of the ingested bacteria were killed. Intracellularly, wild type as well as mutant strains seemed to be killed with the same efficiency. This suggests that the loss of capsular material is associated with loss of capacity to resist uptake by macrophages. This loss of resistance to *in vitro* phagocytosis was associated with a substantial attenuation of the virulence in germfree pigs. All pigs inoculated with the mutant strains survived the experiment and did not show any specific clinical signs of disease. Only some aspecific clinical signs of disease could be observed. Moreover, mutant bacteria could be reisolated from the pigs. This supports the idea that, as in other pathogenic Streptococci, the capsule of *S. suis* acts as an important virulence factor. Transposon mutants prepared by Charland impaired in the capsule

production showed a reduced virulence in pigs and mice. To construct these mutants, the type 2 reference strain S735 was used. We previously showed that this strain is only weakly virulent for young pigs. Moreover, the insertion site of the transposon is unsolved so far.

**As a further example herein, a rapid PCT test for *Streptococcus suis* type 7 is described.**

[0158] Recent epidemiological studies on *Streptococcus suis* infections in pigs indicated that, besides serotypes 1, 2 and 9, serotype 7 is also frequently associated with diseased animals. For the latter serotype, however, no rapid and sensitive diagnostic methods are available. This hampers prevention and control programs. Here we describe the development of a type-specific PCR test for the rapid and sensitive detection of *S. suis* serotype 7. The test is based on DNA sequences of capsular (*cps*) genes specific for serotype 7. These sequences could be identified by cross-hybridization of several individual *cps* genes with the chromosomal DNAs of 35 different *S. suis* serotypes.

[0159] *Streptococcus suis* is an important cause of meningitis, septicemia, arthritis and sudden death in young pigs (69, 70). It can, however, also cause meningitis in man (71). Attempts to control the disease are still hampered by the lack of sufficient knowledge about the epidemiology of the disease and the lack of effective vaccines and sensitive diagnostics.

[0160] *S. suis* strains can be identified and classified by their morphological, biochemical and serological characteristics (70, 73, 74). Serological classification is based on the presence of specific antigenic determinants. Isolated and biochemically characterized *S. suis* cells are agglutinated with a panel of specific sera. These typing methods are very laborious and time-consuming and can only be performed on isolated colonies. Moreover, it has been reported that nonspecific cross-reactions may occur among different types of *S. suis* (75, 76).

[0161] So far, 35 different serotypes have been described (7, 78, 79). *S. suis* serotype 2 is the most prevalent type isolated from diseased pigs, followed by serotypes 9 and 1. However, recently, serotype 7 strains were also frequently isolated from diseased pigs (80, 81, 82). This suggests that infections with *S. suis* serotype 7 strains seem to be an increasing problem. Moreover, the virulence of *S. suis* serotype 7 strains was confirmed by experimental infection of young pigs (83).

[0162] Recently, rapid and sensitive PCR assays specific for serotypes 2 (and 1/2), 1 (and 14) and 9 were developed (84). These assays were based on the *cps* loci of *S. suis* serotypes 2, 1 and 9 (84, 85). However, until now, no rapid and sensitive diagnostic test was available for *S. suis* serotype 7. Herein we describe the development of a PCR test for the rapid and sensitive detection of *S. suis* serotype 7 strains. The test is based on DNA sequences which form a part of the *cps* locus of *S. suis* serotype 7. Compared with the serological serotyping methods, the PCR assay was a rapid, reliable and sensitive assay. Therefore, this test, in combination with the PCR tests which we previously developed for serotypes 1, 2 and 9, will undoubtedly contribute to a more rapid and reliable diagnosis of *S. suis* and may facilitate control and eradication programs.

## Materials and Methods

### Bacterial strains, growth conditions and serotyping.

[0163] The bacterial strains and plasmids used in this study are listed in Table 7. The *S. suis* reference strains were obtained from M. Gottschalk, Canada. *S. suis* strains were grown in Todd-Hewitt broth (code CM189, Oxoid), and plated on Columbia agar blood base (code CM331, Oxoid) containing 6% (v/v) horse blood. *E. coli* strains were grown in Luria broth (86) and plated on Luria broth containing 1.5% (w/v) agar. If required, ampicillin was added to the plates. The *S. suis* strains were serotyped by the slide agglutination test with serotype-specific antibodies (70).

### DNA techniques.

[0164] Routine DNA manipulations and PCR reactions were performed as described by Sambrook et al. (88). Blotting and hybridization were performed as described previously (84, 86).

### DNA sequence analysis.

[0165] DNA sequences were determined on a 373A DNA Sequencing System (Applied Biosystems, Warrington, GB). Samples were prepared by use of an ABI/PRISM dye terminator cycle sequencing ready reaction kit (Applied Biosystems). Custom-made sequencing primers were purchased from Life Technologies. Sequencing data were assembled and analyzed using the

McMollyTetra program. The BLAST program was used to search for protein sequences homologous to the deduced amino acid sequences.

## PCR.

[0166] The primers used for the *cps7H* PCR correspond to the positions 3334-3354 and 3585-3565 in the *S. suis* *cps7* locus.

The sequences were:

5'-AGCTCTAACACGAAATAAGGC-3' (SEQ. ID. No. 7) and

5'-GTCAAACACCCTGGATAGCCG3' (SEQ. ID. No. 8).

The reaction mixtures contained 10 mM Tris-HCl, pH 8.3; 1.5 mM MgCl<sub>2</sub>; 50 mM KCl; 0.2 mM of each of the four deoxynucleotide triphosphates; 1 µM of each of the primers and 1U of AmpliTaq Gold DNA polymerase (Perkin Elmer Applied Biosystems, New Jersey). DNA amplification was carried out in a Perkin Elmer 9600 thermal cycler and the program consisted of an incubation for 10 min at 95°C and 30 cycles of 1 min at 95°C, 2 min at 56°C and 2 min at 72°C.

## Results and discussion

### Cloning of the serotype 7-specific *cps* genes.

[0167] To isolate the type-specific *cps* genes of *S. suis* serotype 7, we used the *cps9E* gene of serotype 9 as a probe to identify chromosomal DNA fragments of type 7 containing homologous DNA sequences (84). A 1.6-kb PstI fragment was identified and cloned in pKUN19. This yielded pCPS7-1 (FIG. 11, part C). In turn, this fragment was used as a probe to identify an overlapping 2.7 kb ScaI-ClaI fragment. pGEM7 containing the latter fragment was designated pCPS7-2 (FIG. 11, part C).

### Analysis of the cloned *cps7* genes.

[0168] The complete nucleotide sequences of the inserts of pCPS7-1, pCPS7-2 were determined. Examination of the *cps7* sequence revealed the presence of two complete and two incomplete open reading frames (ORFs) (FIG. 11, part C). All ORFs are preceded by a ribosome-

binding Site. In accord with the data obtained for the *cps1*, *cps2* and *cps9* genes of serotypes 1, 2 and 9, respectively, the type 7 ORFs are very closely linked to each other. The only significant intergenic gap was that found between *cps7E* and *cps7F* (443 nucleotides). No obvious promoter sequences or potential stem-loop structures were found in this region. This suggests that, as in serotypes 1, 2 and 9, the *cps* genes in serotype 7 form part of an operon.

[0169] An overview of the ORFs and their properties is shown in Table 8. As expected on the basis of the hybridization data (84), the Cps9E and Cps7E proteins showed a high similarity (identity 99%, Table 8). Based on sequence comparisons between Cps9E and Cps7E, the PstI fragment of pCPS7-1 lacks the region encoding the first 371 codons of Cps7E. The C-terminal part of the protein encoded by the *cps7F* gene showed some similarity with the Bp1G protein of *Bordetella pertussis* (88), as well as with the C-terminal part of *S. suis* Cps2E (85). Both Bp1G and Cps2E were suggested to have glycosyltransferase activity and are probably involved in the linkage of the first sugar to the lipid carrier (85, 88). The protein encoded by the *cps7G* gene showed similarity with the Bp1F protein of *Bordetella pertussis* (88). Bp1F is likely to be involved in the biosynthesis of an amino sugar, suggesting a similar function for Cps7G. The protein encoded by the *cps7H* gene showed similarity with the WbdN protein of *E. coli* (89) as well as with the N-terminal part of the Cps2K protein of *S. suis* (81). Both WbdN and Cps2K were suggested to have glycosyltransferase activity (85, 89).

### Serotype 7 specific *cps* genes.

[0170] To determine whether the cloned fragments in pCPS7-1 and pCPS7-2 contained serotype 7-specific DNA sequences, cross-hybridization experiments were performed. DNA fragments of the individual *cps7* genes were amplified by PCR, labeled with <sup>32</sup>P, and used to probe spot blots of chromosomal DNA of the reference strains of 35 different *S. suis* serotypes. The results are summarized in Table 9. As expected, based on the data obtained with the *cps9E* probe (84), the *cps7E* probe hybridized with chromosomal DNA of many different *S. suis* serotypes. The *cps7F* and *cps7G* probes showed hybridization with chromosomal DNA of *S. suis* serotypes 4, 5, 7, 17, and 23. However, the *cps7H* probe hybridized with chromosomal DNA of serotype 7 only, indicating that this gene is specific for serotype 7.



### Type specific PCR.

[0171] We tested whether we could use PCR instead of hybridization for the typing of the *S. suis* serotype 7 strains. For that purpose, we selected an oligonucleotide primer set within the *cps7H* gene with which an amplified fragment of 251-bp was expected. In addition, we included in our analysis several *S. suis* serotype 7 strains, other than the reference strain. These strains were obtained from different countries and were isolated from different organs (Table 7). The results show that indeed a fragment of about 250-bp was amplified with all type 7 strains used (FIG. 12, part B), whereas no PCR products were obtained with serotype 1, 2 and 9 strains (FIG. 12, part A). This suggests that the PCR test, as described here, is a rapid diagnostic tool for the identification of *S. suis* serotype 7 strains. Until now, such a diagnostic test was not available for serotype 7 Strains. Together with the recently developed PCR assays for serotypes 1, 2, 1/2, 14 and 9, this assay may be an important diagnostic tool to detect pigs carrying serotype 2, 1/2, 1, 14, 9 and 7 strains and may facilitate control and eradication programs.

TABLE 1. Bacterial strains and plasmids

strain/plasmid	relevant characteristics	source/reference
<b>Strain</b>		
<i>E. coli</i>		
CC118	PhoA <sup>-</sup>	(28)
XL2 blue	Stratagene	
<i>E. coli</i>		
XL2 blue	Stratagene	
<i>S. suis</i>		
10	virulent serotype 2 strain	(49)
3	serotype 2	(63)
17	serotype 2	(63)
735	reference strain serotype 2	(63)
T15	serotype 2	(63)
6555	reference strain serotype 1	(63)
6388	serotype 1	(63)
6290	serotype 1	(63)
5637	serotype 1	(63)
5673	serotype 1/2	(63)
5679	serotype 1/2	(63)
5928	serotype 1/2	(63)
5934	serotype 1/2	(63)
5209	reference strains serotype 1/2	(63)
5218	reference strain serotype 9	(63)
5973	serotype 9	(63)
6437	serotype 9	(63)
6207	serotype 9	(63)
reference strains	serotypes 1-34	(9, 56, 14)
<i>S. suis</i>		
10	virulent serotype 2 strain	(51)
10cpsB	isogenic cpsB mutant of strain 10	this work
10cpsEF	isogenic cpsEF mutant of strain 10	this work
<b>Plasmid</b>		
pKUN19	replication functions pUC, Amp <sup>R</sup>	(23)
pGEN7zf(+)	replication functions pUC, Amp <sup>R</sup>	Promega Corp.
pIC19R	replication functions pUC, Amp <sup>R</sup>	(29)
pIC20R	replication functions pUC, Amp <sup>R</sup>	(29)
pIC-spc	pIC19R containing spc <sup>R</sup> gene of pDL282	labcollection

pDL282	replication functions of pBR322 and pVT736-1, Amp <sup>R</sup> , Spc <sup>R</sup>	(43)
pPHOS2	pIC-spc containing the truncated <i>phoA</i> gene of pPHO7 as a <i>Pst</i> I- <i>Bam</i> HI fragment	this work
pPHO7	contains truncated <i>phoA</i> gene	(15)
pPHOS7	pPHOS2 containing chromosomal <i>S. suis</i> DNA	this work
pCPS6	pKUN19 containing 6 kb <i>Hind</i> III fragment of <i>cps</i> operon	this work (Fig.1)
pCPS7	pKUN19 containing 3,5 kb <i>Eco</i> RI- <i>Hind</i> III fragment of <i>cps</i> operon	this work (Fig.1)
pCPS11	pCPS7 in which 0.4 kb <i>Pst</i> I- <i>Bam</i> HI fragment of <i>cpsB</i> gene is replaced by Spc <sup>R</sup> gene of pIC-spc	this work (Fig.1)
pCPS17	pKUN19 containing 3.1 kb <i>Kpn</i> I fragment of <i>cps</i> operon	this work (Fig.1)
pCPS18	pKUN19 containing 1.8 kb <i>Sna</i> BI fragment of <i>cps</i> operon	this work (Fig.1)
pCPS20	pKUN19 containing 3.3 kb <i>Xba</i> I- <i>Hind</i> III fragment of <i>cps</i> operon	this work (Fig.1)
pCPS23	pGEM7Zf(+) containing 1.5 kb <i>Mlu</i> I fragment of <i>cps</i> operon	this work (Fig.1)
pCPS25	pIC20R containing 2.5 kb <i>Kpn</i> I- <i>Sal</i> I fragment of pCPS17	this work (Fig.1)
pCPS26	pKUN19 containing 3.0 kb <i>Hind</i> III fragment of <i>cps</i> operon	this work (Fig.1)
pCPS27	pCPS25 containing 2.3 kb <i>Xba</i> I (blunt)- <i>Cla</i> I fragment of pCPS20	this work (Fig.1)
pCPS28	pCPS27 containing the 1.2 kb <i>Pst</i> I- <i>Xho</i> I Spc <sup>R</sup> gene of pIC-spc	this work (Fig.1)
pCPS29	pKUN19 containing 2.2 kb <i>Sac</i> I- <i>Pst</i> I fragment of <i>cps</i> operon	this work (Fig.1)
pCPS1-1	pKUN19 containing 5 kb <i>Eco</i> RV fragment of <i>cps</i> operon of type 1	this work (Fig.1)
pCPS1-2	pKUN19 containing 2.2 kb <i>Hind</i> III fragment of <i>cps</i> operon of type 1	this work (Fig.1)
pCPS9-1	pKUN19 containing 1 kb <i>Hind</i> III- <i>Xba</i> I fragment of <i>cps</i> operon of serotype 9	this work (Fig.1)
pCPS9-2	pKUN19 containing 4.0 kb <i>Xba</i> I- <i>Xba</i> I fragment of <i>cps</i> operon of serotype 9	this work (Fig.1)

Amp<sup>R</sup>: ampicillin resistant  
Spc<sup>R</sup>: spectinomycin resistant  
cps: capsular polysaccharide

Table 1 continued

Table 2. Properties of Orfs in the cps locus of *S. suis* serotype 2 and similarities to gene product  
other bacteria

ORF	nucleotide position in sequence	number of amino acids	GC%	proposed function of gene product	similar gene product (% identity)
Orf22	1 -719	240	44	Unknown	<i>B. subtilis</i> YitS (26%)
Orf2Y	2079-822	419	38	Transcription regulation	<i>B. subtilis</i> YcxD (39%)
Orf2X	2202-2934	244	39	Unknown	<i>H. influenzae</i> YADA (24%)
Cps2A	3041-4484	481	39	Regulation	<i>S. pneumoniae</i> Cps19fA (58%)
Cps2B	4504-5191	229	40	Chain length determination	<i>S. pneumoniae</i> type 3 Orf1 (58%)
Cps2C	5203-5878	225	40	Chain length determination/ Export	<i>S. pneumoniae</i> Cps23fD (63%)
Cps2D	5919-6648	243	38	Unknown	<i>S. pneumoniae</i> CpsB (62%)
Cps2E	6675-8052	459	33	Glycosyltransferase	<i>S. pneumoniae</i> Cps14E (56%)
Cps2F	8089-9256	389	32	Glycosyltransferase	<i>S. pneumoniae</i> Cps23fT
Cps2G	9262-10417	385	36	Glycosyltransferase	<i>S. thermophilus</i> EpsF (25%)
Cps2H	10808-12176	457	31	Glycosyltransferase	<i>S. mutans</i> RGPEC, N (29%)
Cps2I	12213- 13443	410	29	CP polymerase	<i>S. pneumoniae</i> Cps23fI (48%)
Cps2J	13583-14579	332	29	Glycosyltransferase	<i>S. pneumoniae</i> Cps14J (31%)
Cps2K	14574-15576	334	37	Glycosyltransferase	<i>S. pneumoniae</i> Cps14J (40%)

Table 2 continued

"Cps2L"	15618-16635	103	37	Unknown	-
"Cps2M"	16811-17322	-	38	-	<i>S. agalactiae</i> CpsF <sup>N</sup> (77%)
"Cps2N"	17559-18342	-	39	-	<i>E. coli</i> NeuA, <sup>N</sup> (47%)
Cps2O	18401-19802	476	40	Repeat unit transporter	<i>S. agalactiae</i> CpsJ (43%)
Cps2P	20327-21341	338	39	Sialic acid synthesis	<i>S. agalactiae</i> CpsK (41%)
Cps2Q	21355-21865	170	42	Sialic acid synthesis	<i>S. agalactiae</i> NeuB (80%)
Cps2R	21933-22483	184	40	Sialic acid synthesis	<i>E. coli</i> NeuB (59%)
Cps2S	22501-23125	208	42	Sialic acid synthesis	<i>S. agalactiae</i> NeuC <sup>N</sup> (61%)
Cps2T	23136-24366	395	40	Sialic acid synthesis	<i>E. coli</i> NeuC <sup>N</sup> (54%)
"Orf20"	24566-25488	168	42	Transposase	<i>S. agalactiae</i> NeuC <sup>C</sup> (55%)
"Orf2V"	25691-26281	116	37	Transposase	<i>E. coli</i> NeuC <sup>C</sup> (40%)
					<i>E. coli</i> NeuD (32%)
					<i>S. agalactiae</i> CpsF (49%)
					<i>E. coli</i> NeuA (34%)
					<i>S. thermophilus</i> IS1194 (51%)
					<i>S. pneumoniae</i> orf1 (85%)

<sup>1</sup> Predicted by sequence similarity<sup>N</sup> Similarity refers to the amino-terminal part of the gene product<sup>C</sup> Similarity refers to the carboxy-terminal part of the gene product

ORFs between " " are truncated or non-functional as the result of frame-shift or point mutations

Table 3. Properties of Orfs in the cps genes of *S. suis* serotypes 1 and 9 and similarities to gene products of other bacteria

ORF	nucleotide position in sequence	G + C%	number of amino acids	predicted mol. mass (kDa)	predicted pI	proposed function of gene product <sup>1</sup>	similar gene product (% identity)	reference/ accession
Cps1E <sup>2</sup>	1-1363	34%	454	52.2	8.0	Glucosyltransferase	<i>Streptococcus suis</i> Cps2E (86%)	(26)
(48%)							<i>Streptococcus pneumoniae</i> Cps14E (12)	
Cps1F	1374-1821	33%	149	17.3	8.2	Unknown	<i>Streptococcus pneumoniae</i> Cps14F (83%)	(14)
Cps1G	1823-2315	25%	164	19.5	7.5	Glycosyltransferase	<i>Streptococcus pneumoniae</i> Cps14G (50%) (14)	
Cps1H	3035-4202	24%	389	45.5	8.4	CP polymerase	<i>Streptococcus pneumoniae</i> Cps14H (30%) (14)	
Cps1I	4197-					Glycosyltransferase	<i>Streptococcus pneumoniae</i> Cps14J (38%) (13)	
							<i>Lactococcus lactis</i> EpsG (31%) (29)	
							<i>Streptococcus thermophilus</i> EpsI (33%) (28)	
Cps1J						Glycosyltransferase	<i>Streptococcus pneumoniae</i> Cps14J ( )	

Table 3 continued

Cps1K <sup>3</sup>	37%	278	32.5	7.8	Glycosyltransferase	(13)
						<i>Streptococcus pneumoniae</i> Cps14J (44%) (13)
Cps9D <sup>2</sup>	37%	215	24.9	8.1	Unknown	(26)
						<i>Streptococcus suis</i> Cps2D (89%)
Cps9E					Glycosyltransferase	(18)
						<i>Staphylococcus aureus</i> Cap1D (27%)
Cps9F	36%	200	22.3	8.2	Glycosyltransferase	(17)
						<i>Staphylococcus aureus</i> Cap5M (52%)
Cps9G	35%	269	31.5	8.0	Unknown	(43%)
						<i>Actinobacillus actinomycetemcomitans</i> (AB002668_4)
						<i>Haemophilus influenzae</i> lsg (43%) (005081)
Cps9H <sup>3</sup>	30%	143	16.5	7.2	Unknown	(28%) (33)
						<i>Yersinia enterocolitica</i> R8BB

<sup>1</sup> Predicted by sequence similarity

<sup>2</sup> N-terminal part of protein is lacking

<sup>3</sup> C-terminal part of protein is lacking





Table 5. Hybridization of serotypes 1 and 9 *cps* genes with chromosomal DNA of other *S. suis* serotypes

56

[illegible]

TABLE 6. Virulence of wild type and capsular mutant *S. suis* strains in germfree pigs

<i>S. suis</i> strains <sup>1</sup>	pigs/ group (n)	mortality <sup>2</sup> (%)	morbidity <sup>3</sup> (%)	clinical index of the group	spec symptoms <sup>4</sup>	non-spec. symptoms <sup>5</sup>	fever index <sup>7</sup>	leuco- cyte index <sup>8</sup>	isolation of <i>S. suis</i> in pigs [n] per group in	CNS	serosae	joints
10	4	100	100	11	88		43	44	2	3		4
10cpsB	4	0	0	0	10		1	3	1	3		2
10cpsEF	4	0	0	0	0		1	0	1	3		2

50

<sup>1</sup> strain 10 in the wild type strain, strains 10cpsB and 10cpsEF are isogenic capsular mutant strains

<sup>2</sup> piglets which died spontaneously or had to be killed for animal welfare reasons

<sup>3</sup> only considering pigs with specific symptoms

<sup>4</sup> clinical index: % of observations which matched the described criteria

<sup>5</sup> specific symptoms: ataxia, lameness on at least one joint, stiffness

<sup>6</sup> non-specific symptoms: inappetence, depression

<sup>7</sup> % of observations in the experimental group with a body temperature > 40° C

<sup>8</sup> % of blood samples in the group in which number of granulocytes > 10<sup>10</sup>/l

Table 7. Bacterial strains and plasmids

Strain/plasmid	relevant characteristics
<b>Strain</b>	
<i>E. coli</i>	
XL2 blue	
<i>S. suis</i>	
reference strains	serotypes 1-34
5667	serotype 7, tonsil (1993)
7037	serotype 7, organs (1994)
7044	serotype 7, brains (1994)
7068	serotype 7 (1994)
7646	serotype 7 (1994)
7744	serotype 7, lungs (1996)
7759	serotype 7, joints (1996)
8169	serotype 7 (1997)
15913	serotype 7, meninges (1998)
<b>Plasmid</b>	
pKUN19	replication functions pUC, Amp <sup>R</sup>
pGEM72f(+)	replication functions pUC, Amp <sup>R</sup>
pCPS9-1	pKUN19 containing 1 kb <i>HindIII</i> - <i>XbaI</i> fragment of cps operon of serotype 9
pCPS9-2	pKUN19 containing 4.0 kb <i>XbaI</i> - <i>XbaI</i> fragment of cps operon of serotype 9
pCPS7-1	pKUN19 containing 1.6-kb <i>PstI</i> fragment of cps operon of type 7
pCPS7-2	pGEM7 containing 2.7-kb <i>ScaI</i> - <i>ClaI</i> fragment of cps operon of type 7

Amp<sup>R</sup>: ampicillin resistant  
cps: capsular polysaccharide

Table 8. Properties of Orfs in the cps genes of *S. suis* serotype 7 and similarities to gene products of other bacteria

Orf	nucleotide position in sequence	proposed function of gene product	similar gene product (% identity)
Cps7E	1-719	Glycosyltransferase	<i>Streptococcus suis</i> Cps9E (99%)
Cps7F	1164-1863	Glycosyltransferase	<i>Bordetella pertussis</i> Bp1G <sup>1</sup> (43%) <i>Streptococcus suis</i> Cps2E <sup>1</sup> (33%)
Cps7G	1872-3086	Biosynthesis amino sugar	<i>Bordetella pertussis</i> Bp1F (48%)
Cps7H	3104-3737	Glycosyltransferase	<i>Escherichia coli</i> WbdN (35%) <i>Streptococcus suis</i> Cps2K <sup>2</sup> (31%)

<sup>1</sup>similarity refers to the C-terminal part of the gene product

<sup>2</sup>similarity refers to the N-terminal part of the gene product

Table 9. Hybridization of serotype 7 cps probes with chromosomal DNA of *S. suis* serotypes

serotypes	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	1/2			
DNA probes																																						
<i>cps7E</i>	-	-	+	+	+	-	+	-	+	+	+	+	-	-	-	+	+	+	-	-	+	+	+	-	-	-	-	+	+	+	-	-	-	-	+			
<i>cps7F</i>	-	-	-	+	+	-	+	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
<i>cps7G</i>	-	-	-	+	+	+	+	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
<i>cps7H</i>	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
16S rRNA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			